CA3072306A1 - Increased ethanol production by yeast harboring constitutive transcriptional activator mal alleles - Google Patents
Increased ethanol production by yeast harboring constitutive transcriptional activator mal alleles Download PDFInfo
- Publication number
- CA3072306A1 CA3072306A1 CA3072306A CA3072306A CA3072306A1 CA 3072306 A1 CA3072306 A1 CA 3072306A1 CA 3072306 A CA3072306 A CA 3072306A CA 3072306 A CA3072306 A CA 3072306A CA 3072306 A1 CA3072306 A1 CA 3072306A1
- Authority
- CA
- Canada
- Prior art keywords
- yeast
- fermentation
- pathway
- ethanol
- transcriptional activator
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 title claims abstract description 154
- 240000004808 Saccharomyces cerevisiae Species 0.000 title claims abstract description 120
- 238000004519 manufacturing process Methods 0.000 title claims abstract description 39
- 108700028369 Alleles Proteins 0.000 title claims abstract description 37
- 108091006106 transcriptional activators Proteins 0.000 title claims abstract description 27
- 238000000034 method Methods 0.000 claims abstract description 46
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 claims abstract description 31
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 claims abstract description 31
- 229920002472 Starch Polymers 0.000 claims abstract description 17
- 235000019698 starch Nutrition 0.000 claims abstract description 17
- 239000008107 starch Substances 0.000 claims abstract description 17
- 230000004060 metabolic process Effects 0.000 claims abstract description 9
- 108090000623 proteins and genes Proteins 0.000 claims description 98
- 238000000855 fermentation Methods 0.000 claims description 46
- 230000004151 fermentation Effects 0.000 claims description 43
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 39
- 230000037361 pathway Effects 0.000 claims description 36
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 36
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 36
- 229920001184 polypeptide Polymers 0.000 claims description 35
- ZSLZBFCDCINBPY-ZSJPKINUSA-N acetyl-CoA Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCSC(=O)C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 ZSLZBFCDCINBPY-ZSJPKINUSA-N 0.000 claims description 33
- 108010004621 phosphoketolase Proteins 0.000 claims description 30
- 102000004190 Enzymes Human genes 0.000 claims description 21
- 108090000790 Enzymes Proteins 0.000 claims description 21
- 239000000413 hydrolysate Substances 0.000 claims description 14
- 108091033319 polynucleotide Proteins 0.000 claims description 10
- 102000040430 polynucleotide Human genes 0.000 claims description 10
- 239000002157 polynucleotide Substances 0.000 claims description 10
- 241000235070 Saccharomyces Species 0.000 claims description 9
- 229910052799 carbon Inorganic materials 0.000 claims description 8
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 7
- 230000004907 flux Effects 0.000 claims description 7
- 230000004075 alteration Effects 0.000 claims description 6
- 238000012239 gene modification Methods 0.000 claims description 6
- 230000004077 genetic alteration Effects 0.000 claims description 6
- 231100000118 genetic alteration Toxicity 0.000 claims description 6
- 230000005017 genetic modification Effects 0.000 claims description 6
- 235000013617 genetically modified food Nutrition 0.000 claims description 6
- 238000012545 processing Methods 0.000 claims description 6
- 150000001720 carbohydrates Chemical class 0.000 claims description 5
- 235000014633 carbohydrates Nutrition 0.000 claims description 5
- 230000037353 metabolic pathway Effects 0.000 claims description 5
- 102220046415 rs587777600 Human genes 0.000 claims 4
- 108010009736 Protein Hydrolysates Proteins 0.000 claims 1
- 239000000758 substrate Substances 0.000 abstract description 10
- 239000000203 mixture Substances 0.000 abstract description 9
- 230000014509 gene expression Effects 0.000 description 32
- 102000004169 proteins and genes Human genes 0.000 description 32
- 238000012217 deletion Methods 0.000 description 25
- 230000037430 deletion Effects 0.000 description 24
- 102100039459 Myelin and lymphocyte protein Human genes 0.000 description 23
- 210000004027 cell Anatomy 0.000 description 23
- 239000012634 fragment Substances 0.000 description 23
- 108020004414 DNA Proteins 0.000 description 19
- 229940088598 enzyme Drugs 0.000 description 19
- 230000000694 effects Effects 0.000 description 18
- 239000013612 plasmid Substances 0.000 description 18
- 239000000047 product Substances 0.000 description 13
- 101150050575 URA3 gene Proteins 0.000 description 12
- 210000005253 yeast cell Anatomy 0.000 description 11
- 230000006696 biosynthetic metabolic pathway Effects 0.000 description 10
- 150000007523 nucleic acids Chemical class 0.000 description 10
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 9
- 239000008103 glucose Substances 0.000 description 9
- 101100246753 Halobacterium salinarum (strain ATCC 700922 / JCM 11081 / NRC-1) pyrF gene Proteins 0.000 description 8
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 8
- ZXEKIIBDNHEJCQ-UHFFFAOYSA-N isobutanol Chemical compound CC(C)CO ZXEKIIBDNHEJCQ-UHFFFAOYSA-N 0.000 description 8
- 230000004048 modification Effects 0.000 description 8
- 238000012986 modification Methods 0.000 description 8
- 230000035772 mutation Effects 0.000 description 8
- 238000006467 substitution reaction Methods 0.000 description 8
- 101100351264 Candida albicans (strain SC5314 / ATCC MYA-2876) PDC11 gene Proteins 0.000 description 7
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 7
- 101150050255 PDC1 gene Proteins 0.000 description 7
- 108700023175 Phosphate acetyltransferases Proteins 0.000 description 7
- 150000001413 amino acids Chemical class 0.000 description 7
- 238000003556 assay Methods 0.000 description 7
- 230000012010 growth Effects 0.000 description 7
- 238000013518 transcription Methods 0.000 description 7
- 230000035897 transcription Effects 0.000 description 7
- 108091026890 Coding region Proteins 0.000 description 6
- 108091028043 Nucleic acid sequence Proteins 0.000 description 6
- 101100339515 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) HO gene Proteins 0.000 description 6
- 108010081577 aldehyde dehydrogenase (NAD(P)+) Proteins 0.000 description 6
- 230000002829 reductive effect Effects 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- 239000004382 Amylase Substances 0.000 description 5
- 239000000446 fuel Substances 0.000 description 5
- 230000006870 function Effects 0.000 description 5
- BRZYSWJRSDMWLG-CAXSIQPQSA-N geneticin Natural products O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](C(C)O)O2)N)[C@@H](N)C[C@H]1N BRZYSWJRSDMWLG-CAXSIQPQSA-N 0.000 description 5
- 102000039446 nucleic acids Human genes 0.000 description 5
- 108020004707 nucleic acids Proteins 0.000 description 5
- 230000036961 partial effect Effects 0.000 description 5
- 230000001105 regulatory effect Effects 0.000 description 5
- 238000011144 upstream manufacturing Methods 0.000 description 5
- KMZHZAAOEWVPSE-UHFFFAOYSA-N 2,3-dihydroxypropyl acetate Chemical compound CC(=O)OCC(O)CO KMZHZAAOEWVPSE-UHFFFAOYSA-N 0.000 description 4
- SEHFUALWMUWDKS-UHFFFAOYSA-N 5-fluoroorotic acid Chemical compound OC(=O)C=1NC(=O)NC(=O)C=1F SEHFUALWMUWDKS-UHFFFAOYSA-N 0.000 description 4
- 108010073178 Glucan 1,4-alpha-Glucosidase Proteins 0.000 description 4
- 102100022624 Glucoamylase Human genes 0.000 description 4
- 101000579123 Homo sapiens Phosphoglycerate kinase 1 Proteins 0.000 description 4
- AMIMRNSIRUDHCM-UHFFFAOYSA-N Isopropylaldehyde Chemical compound CC(C)C=O AMIMRNSIRUDHCM-UHFFFAOYSA-N 0.000 description 4
- 241000205007 Methanothrix soehngenii Species 0.000 description 4
- KJWZYMMLVHIVSU-IYCNHOCDSA-N PGK1 Chemical compound CCCCC[C@H](O)\C=C\[C@@H]1[C@@H](CCCCCCC(O)=O)C(=O)CC1=O KJWZYMMLVHIVSU-IYCNHOCDSA-N 0.000 description 4
- 102100028251 Phosphoglycerate kinase 1 Human genes 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 4
- 230000001413 cellular effect Effects 0.000 description 4
- 238000010353 genetic engineering Methods 0.000 description 4
- 238000004128 high performance liquid chromatography Methods 0.000 description 4
- 238000003780 insertion Methods 0.000 description 4
- 230000037431 insertion Effects 0.000 description 4
- 239000011159 matrix material Substances 0.000 description 4
- 238000002703 mutagenesis Methods 0.000 description 4
- 231100000350 mutagenesis Toxicity 0.000 description 4
- QHKABHOOEWYVLI-UHFFFAOYSA-N 3-methyl-2-oxobutanoic acid Chemical compound CC(C)C(=O)C(O)=O QHKABHOOEWYVLI-UHFFFAOYSA-N 0.000 description 3
- DBTMGCOVALSLOR-UHFFFAOYSA-N 32-alpha-galactosyl-3-alpha-galactosyl-galactose Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(OC2C(C(CO)OC(O)C2O)O)OC(CO)C1O DBTMGCOVALSLOR-UHFFFAOYSA-N 0.000 description 3
- RXVWSYJTUUKTEA-UHFFFAOYSA-N D-maltotriose Natural products OC1C(O)C(OC(C(O)CO)C(O)C(O)C=O)OC(CO)C1OC1C(O)C(O)C(O)C(CO)O1 RXVWSYJTUUKTEA-UHFFFAOYSA-N 0.000 description 3
- 241000233866 Fungi Species 0.000 description 3
- 240000006024 Lactobacillus plantarum Species 0.000 description 3
- BAWFJGJZGIEFAR-NNYOXOHSSA-O NAD(+) Chemical compound NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 BAWFJGJZGIEFAR-NNYOXOHSSA-O 0.000 description 3
- 108010011939 Pyruvate Decarboxylase Proteins 0.000 description 3
- 101100507950 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) HXT3 gene Proteins 0.000 description 3
- 108700019146 Transgenes Proteins 0.000 description 3
- 230000000397 acetylating effect Effects 0.000 description 3
- 230000001186 cumulative effect Effects 0.000 description 3
- 230000001419 dependent effect Effects 0.000 description 3
- 239000003623 enhancer Substances 0.000 description 3
- 108010008221 formate C-acetyltransferase Proteins 0.000 description 3
- 230000004153 glucose metabolism Effects 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- FYGDTMLNYKFZSV-UHFFFAOYSA-N mannotriose Natural products OC1C(O)C(O)C(CO)OC1OC1C(CO)OC(OC2C(OC(O)C(O)C2O)CO)C(O)C1O FYGDTMLNYKFZSV-UHFFFAOYSA-N 0.000 description 3
- 239000003550 marker Substances 0.000 description 3
- 229920000642 polymer Polymers 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- FYGDTMLNYKFZSV-BYLHFPJWSA-N β-1,4-galactotrioside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@H](CO)O[C@@H](O[C@@H]2[C@@H](O[C@@H](O)[C@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O FYGDTMLNYKFZSV-BYLHFPJWSA-N 0.000 description 3
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
- JTEYKUFKXGDTEU-UHFFFAOYSA-N 2,3-dihydroxy-3-methylbutanoic acid Chemical compound CC(C)(O)C(O)C(O)=O JTEYKUFKXGDTEU-UHFFFAOYSA-N 0.000 description 2
- WTLNOANVTIKPEE-UHFFFAOYSA-N 2-acetyloxypropanoic acid Chemical compound OC(=O)C(C)OC(C)=O WTLNOANVTIKPEE-UHFFFAOYSA-N 0.000 description 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 2
- 108010021809 Alcohol dehydrogenase Proteins 0.000 description 2
- 241000235349 Ascomycota Species 0.000 description 2
- 101100434663 Bacillus subtilis (strain 168) fbaA gene Proteins 0.000 description 2
- 241000221198 Basidiomycota Species 0.000 description 2
- 241000520177 Desulfospira joergensenii Species 0.000 description 2
- 101150095274 FBA1 gene Proteins 0.000 description 2
- 241000207201 Gardnerella vaginalis Species 0.000 description 2
- 108700028146 Genetic Enhancer Elements Proteins 0.000 description 2
- 102100030395 Glycerol-3-phosphate dehydrogenase, mitochondrial Human genes 0.000 description 2
- 102000000587 Glycerolphosphate Dehydrogenase Human genes 0.000 description 2
- 108010041921 Glycerolphosphate Dehydrogenase Proteins 0.000 description 2
- 101001009678 Homo sapiens Glycerol-3-phosphate dehydrogenase, mitochondrial Proteins 0.000 description 2
- 101000962438 Homo sapiens Protein MAL2 Proteins 0.000 description 2
- 235000013965 Lactobacillus plantarum Nutrition 0.000 description 2
- 102000004316 Oxidoreductases Human genes 0.000 description 2
- 108090000854 Oxidoreductases Proteins 0.000 description 2
- 108091005804 Peptidases Proteins 0.000 description 2
- 241000425347 Phyla <beetle> Species 0.000 description 2
- 108010059820 Polygalacturonase Proteins 0.000 description 2
- 239000004365 Protease Substances 0.000 description 2
- 102100039191 Protein MAL2 Human genes 0.000 description 2
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 2
- 101100161410 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) AAP1 gene Proteins 0.000 description 2
- 241000235343 Saccharomycetales Species 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 240000008042 Zea mays Species 0.000 description 2
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 2
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 2
- 125000003275 alpha amino acid group Chemical group 0.000 description 2
- 125000000539 amino acid group Chemical group 0.000 description 2
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical group C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 235000013405 beer Nutrition 0.000 description 2
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 210000000349 chromosome Anatomy 0.000 description 2
- 235000005822 corn Nutrition 0.000 description 2
- 238000004520 electroporation Methods 0.000 description 2
- 230000002255 enzymatic effect Effects 0.000 description 2
- 101150041588 eutE gene Proteins 0.000 description 2
- 108010093305 exopolygalacturonase Proteins 0.000 description 2
- -1 for example Chemical class 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 230000010354 integration Effects 0.000 description 2
- 239000000543 intermediate Substances 0.000 description 2
- 229940072205 lactobacillus plantarum Drugs 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000000750 progressive effect Effects 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000010076 replication Effects 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 239000013598 vector Substances 0.000 description 2
- 235000014101 wine Nutrition 0.000 description 2
- FQVLRGLGWNWPSS-BXBUPLCLSA-N (4r,7s,10s,13s,16r)-16-acetamido-13-(1h-imidazol-5-ylmethyl)-10-methyl-6,9,12,15-tetraoxo-7-propan-2-yl-1,2-dithia-5,8,11,14-tetrazacycloheptadecane-4-carboxamide Chemical compound N1C(=O)[C@@H](NC(C)=O)CSSC[C@@H](C(N)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](C)NC(=O)[C@@H]1CC1=CN=CN1 FQVLRGLGWNWPSS-BXBUPLCLSA-N 0.000 description 1
- PKAUICCNAWQPAU-UHFFFAOYSA-N 2-(4-chloro-2-methylphenoxy)acetic acid;n-methylmethanamine Chemical compound CNC.CC1=CC(Cl)=CC=C1OCC(O)=O PKAUICCNAWQPAU-UHFFFAOYSA-N 0.000 description 1
- 108020005065 3' Flanking Region Proteins 0.000 description 1
- 108020005029 5' Flanking Region Proteins 0.000 description 1
- 108010011619 6-Phytase Proteins 0.000 description 1
- 108010000700 Acetolactate synthase Proteins 0.000 description 1
- 102100026026 Acyl-CoA synthetase short-chain family member 3, mitochondrial Human genes 0.000 description 1
- 101000823183 Alcaligenes faecalis Aralkylamine dehydrogenase heavy chain Proteins 0.000 description 1
- 101000823182 Alcaligenes faecalis Aralkylamine dehydrogenase light chain Proteins 0.000 description 1
- 102000007698 Alcohol dehydrogenase Human genes 0.000 description 1
- 102100034035 Alcohol dehydrogenase 1A Human genes 0.000 description 1
- 101100394866 Arabidopsis thaliana HIPP47 gene Proteins 0.000 description 1
- 241000122821 Aspergillus kawachii Species 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 102100026189 Beta-galactosidase Human genes 0.000 description 1
- 102100032487 Beta-mannosidase Human genes 0.000 description 1
- NRLNWDYLCHJVLJ-BTVCFUMJSA-N C(C)(=O)OCC(O)CO.O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO Chemical compound C(C)(=O)OCC(O)CO.O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO NRLNWDYLCHJVLJ-BTVCFUMJSA-N 0.000 description 1
- 108091033409 CRISPR Proteins 0.000 description 1
- 101100022254 Candida albicans MAL2 gene Proteins 0.000 description 1
- 108090000489 Carboxy-Lyases Proteins 0.000 description 1
- 102000004031 Carboxy-Lyases Human genes 0.000 description 1
- 108010059892 Cellulase Proteins 0.000 description 1
- 108010077544 Chromatin Proteins 0.000 description 1
- 108020004705 Codon Proteins 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 102100022768 D-beta-hydroxybutyrate dehydrogenase, mitochondrial Human genes 0.000 description 1
- 101710088194 Dehydrogenase Proteins 0.000 description 1
- 108700016168 Dihydroxy-acid dehydratases Proteins 0.000 description 1
- 101710121765 Endo-1,4-beta-xylanase Proteins 0.000 description 1
- 108090000371 Esterases Proteins 0.000 description 1
- 102100028121 Fos-related antigen 2 Human genes 0.000 description 1
- 101150059691 GPP2 gene Proteins 0.000 description 1
- 241001123946 Gaga Species 0.000 description 1
- 108700007698 Genetic Terminator Regions Proteins 0.000 description 1
- 101000892220 Geobacillus thermodenitrificans (strain NG80-2) Long-chain-alcohol dehydrogenase 1 Proteins 0.000 description 1
- XYZZKVRWGOWVGO-UHFFFAOYSA-N Glycerol-phosphate Chemical compound OP(O)(O)=O.OCC(O)CO XYZZKVRWGOWVGO-UHFFFAOYSA-N 0.000 description 1
- 101000780443 Homo sapiens Alcohol dehydrogenase 1A Proteins 0.000 description 1
- 101000903373 Homo sapiens D-beta-hydroxybutyrate dehydrogenase, mitochondrial Proteins 0.000 description 1
- 101001059934 Homo sapiens Fos-related antigen 2 Proteins 0.000 description 1
- 101001072574 Homo sapiens Glycerol-3-phosphate dehydrogenase [NAD(+)], cytoplasmic Proteins 0.000 description 1
- 101000727821 Homo sapiens RING1 and YY1-binding protein Proteins 0.000 description 1
- 108010028688 Isoamylase Proteins 0.000 description 1
- 102000004195 Isomerases Human genes 0.000 description 1
- 108090000769 Isomerases Proteins 0.000 description 1
- 241000235649 Kluyveromyces Species 0.000 description 1
- 108010029541 Laccase Proteins 0.000 description 1
- 241000858110 Lachancea Species 0.000 description 1
- 108010059881 Lactase Proteins 0.000 description 1
- 102000003960 Ligases Human genes 0.000 description 1
- 108090000364 Ligases Proteins 0.000 description 1
- 108090001060 Lipase Proteins 0.000 description 1
- 239000004367 Lipase Substances 0.000 description 1
- 102000004882 Lipase Human genes 0.000 description 1
- 240000003183 Manihot esculenta Species 0.000 description 1
- 235000016735 Manihot esculenta subsp esculenta Nutrition 0.000 description 1
- 101100446038 Mus musculus Fabp5 gene Proteins 0.000 description 1
- 108700026244 Open Reading Frames Proteins 0.000 description 1
- 102000003992 Peroxidases Human genes 0.000 description 1
- 108700019535 Phosphoprotein Phosphatases Proteins 0.000 description 1
- 102000045595 Phosphoprotein Phosphatases Human genes 0.000 description 1
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 1
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 1
- LCTONWCANYUPML-UHFFFAOYSA-M Pyruvate Chemical compound CC(=O)C([O-])=O LCTONWCANYUPML-UHFFFAOYSA-M 0.000 description 1
- 102100029760 RING1 and YY1-binding protein Human genes 0.000 description 1
- 108091030071 RNAI Proteins 0.000 description 1
- 108020005091 Replication Origin Proteins 0.000 description 1
- 101100010928 Saccharolobus solfataricus (strain ATCC 35092 / DSM 1617 / JCM 11322 / P2) tuf gene Proteins 0.000 description 1
- 101100055274 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) ALD6 gene Proteins 0.000 description 1
- 101100082596 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) PDC5 gene Proteins 0.000 description 1
- 101100519200 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) PDC6 gene Proteins 0.000 description 1
- 240000000111 Saccharum officinarum Species 0.000 description 1
- 235000007201 Saccharum officinarum Nutrition 0.000 description 1
- 241000235346 Schizosaccharomyces Species 0.000 description 1
- 238000012300 Sequence Analysis Methods 0.000 description 1
- 108091081024 Start codon Proteins 0.000 description 1
- 101710172711 Structural protein Proteins 0.000 description 1
- 101150001810 TEAD1 gene Proteins 0.000 description 1
- 101150074253 TEF1 gene Proteins 0.000 description 1
- 102100029898 Transcriptional enhancer factor TEF-1 Human genes 0.000 description 1
- 102000004357 Transferases Human genes 0.000 description 1
- 108090000992 Transferases Proteins 0.000 description 1
- 108010043652 Transketolase Proteins 0.000 description 1
- 102000014701 Transketolase Human genes 0.000 description 1
- 102100029677 Trehalase Human genes 0.000 description 1
- 108010087472 Trehalase Proteins 0.000 description 1
- 241000223259 Trichoderma Species 0.000 description 1
- LIPOUNRJVLNBCD-UHFFFAOYSA-N acetyl dihydrogen phosphate Chemical compound CC(=O)OP(O)(O)=O LIPOUNRJVLNBCD-UHFFFAOYSA-N 0.000 description 1
- 230000021736 acetylation Effects 0.000 description 1
- 238000006640 acetylation reaction Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 238000010564 aerobic fermentation Methods 0.000 description 1
- 108090000637 alpha-Amylases Proteins 0.000 description 1
- 108010028144 alpha-Glucosidases Proteins 0.000 description 1
- 102000016679 alpha-Glucosidases Human genes 0.000 description 1
- 229960000723 ampicillin Drugs 0.000 description 1
- 230000000692 anti-sense effect Effects 0.000 description 1
- 108010005774 beta-Galactosidase Proteins 0.000 description 1
- 108010055059 beta-Mannosidase Proteins 0.000 description 1
- 230000027455 binding Effects 0.000 description 1
- 102000023732 binding proteins Human genes 0.000 description 1
- 108091008324 binding proteins Proteins 0.000 description 1
- 230000008238 biochemical pathway Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 238000006664 bond formation reaction Methods 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 150000001721 carbon Chemical group 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 230000033077 cellular process Effects 0.000 description 1
- 229940106157 cellulase Drugs 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 230000007073 chemical hydrolysis Effects 0.000 description 1
- 238000007385 chemical modification Methods 0.000 description 1
- 210000003483 chromatin Anatomy 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 230000009260 cross reactivity Effects 0.000 description 1
- 108010005400 cutinase Proteins 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000007071 enzymatic hydrolysis Effects 0.000 description 1
- 238000006047 enzymatic hydrolysis reaction Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 235000019985 fermented beverage Nutrition 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 230000009368 gene silencing by RNA Effects 0.000 description 1
- 230000013595 glycosylation Effects 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 229940059442 hemicellulase Drugs 0.000 description 1
- 108010002430 hemicellulase Proteins 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 150000004715 keto acids Chemical class 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 229940116108 lactase Drugs 0.000 description 1
- 235000019421 lipase Nutrition 0.000 description 1
- 230000029226 lipidation Effects 0.000 description 1
- 101150083490 mal1 gene Proteins 0.000 description 1
- 101150088659 mal3 gene Proteins 0.000 description 1
- 108010037640 maltose permease Proteins 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000010297 mechanical methods and process Methods 0.000 description 1
- 230000005226 mechanical processes and functions Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 235000013379 molasses Nutrition 0.000 description 1
- 238000001823 molecular biology technique Methods 0.000 description 1
- 238000002887 multiple sequence alignment Methods 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 101150079312 pgk1 gene Proteins 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 229940085127 phytase Drugs 0.000 description 1
- 238000003752 polymerase chain reaction Methods 0.000 description 1
- 239000004810 polytetrafluoroethylene Substances 0.000 description 1
- 229920001343 polytetrafluoroethylene Polymers 0.000 description 1
- 230000001323 posttranslational effect Effects 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 210000003705 ribosome Anatomy 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 239000013605 shuttle vector Substances 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 230000007306 turnover Effects 0.000 description 1
- 238000009423 ventilation Methods 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/14—Fungi; Culture media therefor
- C12N1/16—Yeasts; Culture media therefor
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02E—REDUCTION OF GREENHOUSE GAS [GHG] EMISSIONS, RELATED TO ENERGY GENERATION, TRANSMISSION OR DISTRIBUTION
- Y02E50/00—Technologies for the production of fuel of non-fossil origin
- Y02E50/10—Biofuels, e.g. bio-diesel
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Biomedical Technology (AREA)
- Botany (AREA)
- Virology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Described are compositions and methods relating to modified yeast harboring constitutive transcriptional activator MAL alleles. The yeast produces an increased amount of ethanol, or have an increased rate of ethanol production, which does not appear to be the result of maltose metabolism. Such yeast is particularly useful for ethanol production utilizing starch substrates.
Description
INCREASED ETHANOL PRODUCTION BY YEAST HARBORING
CONSTITUTIVE TRANSCRIPTIONAL ACTIVATOR MAL ALLELES
TECHNICAL FIELD
[01] The present compositions and methods relate to modified yeast harboring constitutive transcriptional activator MAL alleles. The yeast produces an increased amount of ethanol that does not appear to be the result of maltose metabolism. Such yeast is particularly useful for large-scale ethanol production from starch substrates.
BACKGROUND
CONSTITUTIVE TRANSCRIPTIONAL ACTIVATOR MAL ALLELES
TECHNICAL FIELD
[01] The present compositions and methods relate to modified yeast harboring constitutive transcriptional activator MAL alleles. The yeast produces an increased amount of ethanol that does not appear to be the result of maltose metabolism. Such yeast is particularly useful for large-scale ethanol production from starch substrates.
BACKGROUND
[02] The first generation of yeast-based ethanol production converts sugars into fuel ethanol. The annual fuel ethanol production by yeast is about 90 billion liters worldwide (Gombert, A.K. and van Mar. A.J. (2015) Curr. Op/n. Biotechnol. 33:81-86). It is estimated that about 70% of the cost of ethanol production is the feedstock.
Since the production volume is so large, even small yield improvements will have massive economic impact across the industry.
Since the production volume is so large, even small yield improvements will have massive economic impact across the industry.
[03] Yeast, such as Saccharomyces, are capable of metabolizing a number of mono and di-saccharides, including maltose. Maltose fermentation in Saccharomyces involves at least one of five, apparently-redundant, unlinked MAL loci, referred to as MAL1 , MAL2, MAL3, MAL4 and M4L5 (see, e.g., Needleman, R.B. (1991)Mol. Microbiol. 9:2079-84). As illustrated in Figure 1, each locus includes three genes, encoding (i) a maltose permease, (ii) a maltase and (iii) a transcriptional activator (Kim, J. and. Michels, C.A. (1988) Curr.
Genet. 14:319-23 and Cheng, Q. and Michels (1989) Genetics 123:477-84. The genes are conventionally numbered 1, 2 and 3, respectively, such that the genes at the MAL2 locus, for example, are numbered MAL21, MAL22 and MAL23 , respectively.
Genet. 14:319-23 and Cheng, Q. and Michels (1989) Genetics 123:477-84. The genes are conventionally numbered 1, 2 and 3, respectively, such that the genes at the MAL2 locus, for example, are numbered MAL21, MAL22 and MAL23 , respectively.
[04] Transcription of MAL genes is induced by maltose and repressed by glucose;
however, constitutive mutations have been identified at all MAL loci (Winge, 0. and Roberts, C. (1950) C. R. Tray. Lab. Carlsberg Ser. Physiol. 25:35-81, Kahn, N.A. and Eaton, N.R.
(1971)Mol. Gen. Genet. 112: 317-22; Charronm, J. and Michels, C.A. (1987) Genetics 116 23-31; Zimmerman and Eaton, N.R. (1974)Mol. Gen. Genet. 134 261-271; Rodicio, R.
(1986) Curr. Genet. 11:235-41 and Ten Berge, A.M.A. et al. (1973)Mol. Gen.
Genet. 125:
139-46.
however, constitutive mutations have been identified at all MAL loci (Winge, 0. and Roberts, C. (1950) C. R. Tray. Lab. Carlsberg Ser. Physiol. 25:35-81, Kahn, N.A. and Eaton, N.R.
(1971)Mol. Gen. Genet. 112: 317-22; Charronm, J. and Michels, C.A. (1987) Genetics 116 23-31; Zimmerman and Eaton, N.R. (1974)Mol. Gen. Genet. 134 261-271; Rodicio, R.
(1986) Curr. Genet. 11:235-41 and Ten Berge, A.M.A. et al. (1973)Mol. Gen.
Genet. 125:
139-46.
[05] Maltose is present at low levels in commercial-scale, starch-hydrolysates, typically, as an undesirable, DP2-component, which is not likely to be a significant source of additional ethanol. Moreover, transcription ofMAL genes is repressed by high levels of glucose, making it difficult for yeast to utilize maltose under high-glucose conditions, such as those that exist during fuel ethanol production. Deliberate expression of maltose-metabolizing enzymes may in fact slow glucose metabolism and waste carbon, which is unacceptable given the demands of ethanol producers.
SUMMARY
SUMMARY
[06] The present compositions and methods relate to modified yeast harboring constitutive transcriptional activator MAL alleles. While such yeast is presumably capable of metabolizing maltose, even in the presence of glucose, the yeast appears to produce an increased amount of ethanol that is not necessarily the result of maltose metabolism. Aspects and embodiments of the compositions and methods are described in the following, independently-numbered, paragraphs.
1. In one aspect, a method for increasing the amount of alcohol produced from fermentation of a starch hydrolysate and/or increasing the rate of production of alcohol from fermentation of a starch hydrolysate is provided, comprising fermenting the starch hydrolysate with modified yeast harboring a constitutive transcriptional activator MAL
allele, where in the modified yeast produces an increased amount of ethanol at the end of fermentation or an increased amount of ethanol over a period of time compared to the amount of ethanol produced by an otherwise-identical parental yeast.
2. In some embodiments of the method of paragraph 1, at least a portion of the increased amount of ethanol cannot be attributed to maltose fermentation based on carbon flux through a maltose metabolic pathway.
3. In some embodiments of the method of paragraph 1 or 2, the level of maltose in the starch hydrolysate at the end of fermentation is about the same as the level of maltose in the starch hydrolysate at the beginning of fermentation, 4. In some embodiments of the method of any of the preceding paragraphs, the amount of maltose in the starch hydrolysate at the beginning of fermentation is no greater than 10 g/L.
5. In some embodiments of the method of any of the preceding paragraphs, the yeast harboring a constitutive transcriptional activator MAL allele further comprises a genetic alteration that introduces a polynucleotide encoding a polypeptide in the phosphoketolase pathway.
6. In some embodiments of the method of any of the preceding paragraphs, the yeast harboring a constitutive transcriptional activator MAL allele further comprises an alteration in the glycerol pathway and/or the acetyl-CoA pathway.
1. In one aspect, a method for increasing the amount of alcohol produced from fermentation of a starch hydrolysate and/or increasing the rate of production of alcohol from fermentation of a starch hydrolysate is provided, comprising fermenting the starch hydrolysate with modified yeast harboring a constitutive transcriptional activator MAL
allele, where in the modified yeast produces an increased amount of ethanol at the end of fermentation or an increased amount of ethanol over a period of time compared to the amount of ethanol produced by an otherwise-identical parental yeast.
2. In some embodiments of the method of paragraph 1, at least a portion of the increased amount of ethanol cannot be attributed to maltose fermentation based on carbon flux through a maltose metabolic pathway.
3. In some embodiments of the method of paragraph 1 or 2, the level of maltose in the starch hydrolysate at the end of fermentation is about the same as the level of maltose in the starch hydrolysate at the beginning of fermentation, 4. In some embodiments of the method of any of the preceding paragraphs, the amount of maltose in the starch hydrolysate at the beginning of fermentation is no greater than 10 g/L.
5. In some embodiments of the method of any of the preceding paragraphs, the yeast harboring a constitutive transcriptional activator MAL allele further comprises a genetic alteration that introduces a polynucleotide encoding a polypeptide in the phosphoketolase pathway.
6. In some embodiments of the method of any of the preceding paragraphs, the yeast harboring a constitutive transcriptional activator MAL allele further comprises an alteration in the glycerol pathway and/or the acetyl-CoA pathway.
7. In some embodiments of the method of any of the preceding paragraphs, the yeast harboring a constitutive transcriptional activator MAL allele further comprises disruption of a gene encoding DLs1.
8. In some embodiments of the method of any of the preceding paragraphs, the yeast harboring a constitutive transcriptional activator MAL allele comprises an exogenous gene encoding a carbohydrate processing enzyme.
9. In some embodiments of the method of any of the preceding paragraphs, the yeast is a Saccharomyces spp.
10. In another aspect, modified yeast comprising a constitutive transcriptional activator MAL allele, and at least one additional genetic modification not associated with maltose metabolism are provided, which yeast produces during fermentation an increased amount of ethanol at the end of fermentation compared to the amount produced by an otherwise identical parental yeast when grown in a starch hydrolysate.
11. In some embodiments of the modified yeast of paragraph 10, the yeast further comprises a genetic alteration that introduces a polynucleotide encoding a polypeptide in the phosphoketolase pathway.
12. In some embodiments of the modified yeast of paragraph 10 or 11, the yeast further comprises an alteration in the glycerol pathway and/or the acetyl-CoA pathway.
13. In some embodiments of the modified yeast of any of paragraphs 10-12, the yeast further comprises a disruption of a gene encoding DLs1.
14. In some embodiments of the modified yeast of any of paragraphs 10-13, the yeast further comprises an exogenous gene encoding a carbohydrate processing enzyme.
15. In some embodiments of the modified yeast of any of paragraphs 10-14, the yeast is a Saccharomyces spp.
[07] These and other aspects and embodiments of present modified cells and methods will be apparent from the description, including the accompanying Drawings/Figures.
BRIEF DESCRIPTION OF THE DRAWINGS
[08] Figure 1 is a diagram of a typical MAL loci, and its regulation by maltose and glucose [09] Figure 2 depicts a MAL23c expression cassette.
[010] Figure 3 is a map of plasmid pHX19.
[011] Figure 4 is comparison of cumulative CO2 pressure index during fermentation with strains FG and A28.
[012] Figure 5 is a map of plasmid pZKAP1M-(H3C19).
[013] Figure 6 is a map of plasmid pTOPO II-Blunt ura3-loxP-KanMX-loxP-ura3.
[014] Figure 7 is a map of plasmid pGAL-Cre-316.
[015] Figure 8 is comparison of cumulative CO2 pressure index during fermentation with RHY723 and its parent strain GPY10008.
DETAILED DESCRIPTION
I. Definitions
[07] These and other aspects and embodiments of present modified cells and methods will be apparent from the description, including the accompanying Drawings/Figures.
BRIEF DESCRIPTION OF THE DRAWINGS
[08] Figure 1 is a diagram of a typical MAL loci, and its regulation by maltose and glucose [09] Figure 2 depicts a MAL23c expression cassette.
[010] Figure 3 is a map of plasmid pHX19.
[011] Figure 4 is comparison of cumulative CO2 pressure index during fermentation with strains FG and A28.
[012] Figure 5 is a map of plasmid pZKAP1M-(H3C19).
[013] Figure 6 is a map of plasmid pTOPO II-Blunt ura3-loxP-KanMX-loxP-ura3.
[014] Figure 7 is a map of plasmid pGAL-Cre-316.
[015] Figure 8 is comparison of cumulative CO2 pressure index during fermentation with RHY723 and its parent strain GPY10008.
DETAILED DESCRIPTION
I. Definitions
[016] Prior to describing the present yeast and methods in detail, the following terms are defined for clarity. Terms not defined should be accorded their ordinary meanings as used in the relevant art.
[017] As used herein, the term "alcohol" refers to an organic compound in which a hydroxyl functional group (-OH) is bound to a saturated carbon atom.
[018] As used herein, the terms "yeast cells", yeast strains, or simply "yeast" refer to organisms from the phyla Ascomycota and Basidiomycota. Exemplary yeast is budding yeast from the order Saccharomycetales. Particular examples of yeast are Saccharomyces spp., including but not limited to S. cerevisiae. Yeast include organisms used for the production of fuel alcohol as well as organisms used for the production of potable alcohol, including specialty and proprietary yeast strains used to make distinctive-tasting beers, wines, and other fermented beverages.
[019] As used herein, the phrase "engineered yeast cells," "variant yeast cells," "modified yeast cells," or similar phrases, refer to yeast that include genetic modifications and characteristics described herein. Variant/modified yeast do not include naturally occurring yeast.
[020] As used herein, the terms "polypeptide" and "protein" (and their respective plural forms) are used interchangeably to refer to polymers of any length comprising amino acid residues linked by peptide bonds. The conventional one-letter or three-letter codes for amino acid residues are used herein and all sequence are presented from an N-terminal to C-terminal direction. The polymer can comprise modified amino acids, and it can be interrupted by non-amino acids. The terms also encompass an amino acid polymer that has been modified naturally or by intervention; for example, disulfide bond formation, glycosylation, lipidation, acetylation, phosphorylation, or any other manipulation or modification, such as conjugation with a labeling component. Also included within the definition are, for example, polypeptides containing one or more analogs of an amino acid (including, for example, unnatural amino acids, etc.), as well as other modifications known in the art.
[021] As used herein, functionally and/or structurally similar proteins are considered to be "related proteins", or "homologs". Such proteins can be derived from organisms of different genera and/or species, or different classes of organisms (e.g., bacteria and fungi), or artificially designed. Related proteins also encompass homologs determined by primary sequence analysis, determined by secondary or tertiary structure analysis, or determined by immunological cross-reactivity, or determined by their functions.
[022] As used herein, the term "homologous protein" refers to a protein that has similar activity and/or structure to a reference protein. It is not intended that homologs necessarily be evolutionarily related. Thus, it is intended that the term encompass the same, similar, or corresponding enzyme(s) (i.e., in terms of structure and function) obtained from different organisms. In some embodiments, it is desirable to identify a homolog that has a quaternary, tertiary and/or primary structure similar to the reference protein. In some embodiments, homologous proteins induce similar immunological response(s) as a reference protein. In some embodiments, homologous proteins are engineered to produce enzymes with desired activity(ies).
[023] The degree of homology between sequences can be determined using any suitable method known in the art (see, e.g., Smith and Waterman (1981) Adv. Appl. Math.
2:482;
Needleman and Wunsch (1970) J Mol. Biol., 48:443; Pearson and Lipman (1988) Proc. Natl.
Acad. Sci. USA 85:2444; programs such as GAP, BESTFIT, FASTA, and TFASTA in the Wisconsin Genetics Software Package (Genetics Computer Group, Madison, WI);
and Devereux et at. (1984) Nucleic Acids Res. 12:387-95).
2:482;
Needleman and Wunsch (1970) J Mol. Biol., 48:443; Pearson and Lipman (1988) Proc. Natl.
Acad. Sci. USA 85:2444; programs such as GAP, BESTFIT, FASTA, and TFASTA in the Wisconsin Genetics Software Package (Genetics Computer Group, Madison, WI);
and Devereux et at. (1984) Nucleic Acids Res. 12:387-95).
[024] For example, PILEUP is a useful program to determine sequence homology levels.
PILEUP creates a multiple sequence alignment from a group of related sequences using progressive, pair-wise alignments. It can also plot a tree showing the clustering relationships used to create the alignment. PILEUP uses a simplification of the progressive alignment method of Feng and Doolittle, (Feng and Doolittle (1987) J Mol. Evol. 35:351-60). The method is similar to that described by Higgins and Sharp ((1989) CABIOS 5:151-53). Useful PILEUP parameters including a default gap weight of 3.00, a default gap length weight of 0.10, and weighted end gaps. Another example of a useful algorithm is the BLAST
algorithm, described by Altschul et at. ((1990)1 Mol. Biol. 215:403-10) and Karlin et at.
((1993) Proc. Natl. Acad. Sci. USA 90:5873-87). One particularly useful BLAST
program is the WU-BLAST-2 program (see, e.g., Altschul et al. (1996) Meth. Enzymol.
266:460-80).
Parameters "W," "T," and "X" determine the sensitivity and speed of the alignment. The BLAST program uses as defaults a word-length (W) of 11, the BLOSUM62 scoring matrix (see, e.g., Henikoff and Henikoff (1989) Proc. Natl. Acad. Sci. USA 89:10915) alignments (B) of 50, expectation (E) of 10, M'5, N'-4, and a comparison of both strands.
PILEUP creates a multiple sequence alignment from a group of related sequences using progressive, pair-wise alignments. It can also plot a tree showing the clustering relationships used to create the alignment. PILEUP uses a simplification of the progressive alignment method of Feng and Doolittle, (Feng and Doolittle (1987) J Mol. Evol. 35:351-60). The method is similar to that described by Higgins and Sharp ((1989) CABIOS 5:151-53). Useful PILEUP parameters including a default gap weight of 3.00, a default gap length weight of 0.10, and weighted end gaps. Another example of a useful algorithm is the BLAST
algorithm, described by Altschul et at. ((1990)1 Mol. Biol. 215:403-10) and Karlin et at.
((1993) Proc. Natl. Acad. Sci. USA 90:5873-87). One particularly useful BLAST
program is the WU-BLAST-2 program (see, e.g., Altschul et al. (1996) Meth. Enzymol.
266:460-80).
Parameters "W," "T," and "X" determine the sensitivity and speed of the alignment. The BLAST program uses as defaults a word-length (W) of 11, the BLOSUM62 scoring matrix (see, e.g., Henikoff and Henikoff (1989) Proc. Natl. Acad. Sci. USA 89:10915) alignments (B) of 50, expectation (E) of 10, M'5, N'-4, and a comparison of both strands.
[025] As used herein, the phrases "substantially similar" and "substantially identical," in the context of at least two nucleic acids or polypeptides, typically means that a polynucleotide or polypeptide comprises a sequence that has at least about 70% identity, at least about 75%
identity, at least about 80% identity, at least about 85% identity, at least about 90% identity, at least about 91% identity, at least about 92% identity, at least about 93%
identity, at least about 94% identity, at least about 95% identity, at least about 96% identity, at least about 97% identity, at least about 98% identity, or even at least about 99%
identity, or more, compared to the reference (i.e., wild-type) sequence. Percent sequence identity is calculated using CLUSTAL W algorithm with default parameters. See Thompson et at. (1994) Nucleic Acids Res. 22:4673-4680. Default parameters for the CLUSTAL W algorithm are:
Gap opening penalty: 10.0 Gap extension penalty: 0.05 Protein weight matrix: BLOSUM series DNA weight matrix: IUB
Delay divergent sequences %: 40 Gap separation distance: 8 DNA transitions weight: 0.50 List hydrophilic residues: GP SNDQEKR
Use negative matrix: OFF
Toggle Residue specific penalties: ON
Toggle hydrophilic penalties: ON
Toggle end gap separation penalty OFF
identity, at least about 80% identity, at least about 85% identity, at least about 90% identity, at least about 91% identity, at least about 92% identity, at least about 93%
identity, at least about 94% identity, at least about 95% identity, at least about 96% identity, at least about 97% identity, at least about 98% identity, or even at least about 99%
identity, or more, compared to the reference (i.e., wild-type) sequence. Percent sequence identity is calculated using CLUSTAL W algorithm with default parameters. See Thompson et at. (1994) Nucleic Acids Res. 22:4673-4680. Default parameters for the CLUSTAL W algorithm are:
Gap opening penalty: 10.0 Gap extension penalty: 0.05 Protein weight matrix: BLOSUM series DNA weight matrix: IUB
Delay divergent sequences %: 40 Gap separation distance: 8 DNA transitions weight: 0.50 List hydrophilic residues: GP SNDQEKR
Use negative matrix: OFF
Toggle Residue specific penalties: ON
Toggle hydrophilic penalties: ON
Toggle end gap separation penalty OFF
[026] Another indication that two polypeptides are substantially identical is that the first polypeptide is immunologically cross-reactive with the second polypeptide.
Typically, polypeptides that differ by conservative amino acid substitutions are immunologically cross-reactive. Thus, a polypeptide is substantially identical to a second polypeptide, for example, where the two peptides differ only by a conservative substitution. Another indication that two nucleic acid sequences are substantially identical is that the two molecules hybridize to each other under stringent conditions (e.g., within a range of medium to high stringency).
Typically, polypeptides that differ by conservative amino acid substitutions are immunologically cross-reactive. Thus, a polypeptide is substantially identical to a second polypeptide, for example, where the two peptides differ only by a conservative substitution. Another indication that two nucleic acid sequences are substantially identical is that the two molecules hybridize to each other under stringent conditions (e.g., within a range of medium to high stringency).
[027] As used herein, the term "gene" is synonymous with the term "allele" in referring to a nucleic acid that encodes and directs the expression of a protein or RNA.
Vegetative forms of filamentous fungi are generally haploid, therefore a single copy of a specified gene (i.e., a single allele) is sufficient to confer a specified phenotype. The term "allele" is generally preferred when an organism contains more than one similar genes, in which case each different similar gene is referred to as a distinct "allele."
Vegetative forms of filamentous fungi are generally haploid, therefore a single copy of a specified gene (i.e., a single allele) is sufficient to confer a specified phenotype. The term "allele" is generally preferred when an organism contains more than one similar genes, in which case each different similar gene is referred to as a distinct "allele."
[028] As used herein, "constitutive" expression refers to the production of a polypeptide encoded by a particular gene under essentially all typical growth conditions, as opposed to "conditional" expression, which requires the presence of a particular substrate, temperature, or the like to induce or activate expression.
[029] As used herein, the term "expressing a polypeptide" and similar terms refers to the cellular process of producing a polypeptide using the translation machinery (e.g., ribosomes) of the cell.
[030] As used herein, "overexpressing a polypeptide," "increasing the expression of a polypeptide," and similar terms, refer to expressing a polypeptide at higher-than-normal levels compared to those observed with parental or "wild-type cells that do not include a specified genetic modification.
[031] As used herein, an "expression cassette" refers to a DNA fragment that includes a promoter, and amino acid coding region and a terminator (i.e., promoter:
:amino acid coding region: :terminator) and other nucleic acid sequence needed to allow the encoded polypeptide to be produced in a cell. Expression cassettes can be exogenous (i.e., introduced into a cell) or endogenous (i.e., extant in a cell).
:amino acid coding region: :terminator) and other nucleic acid sequence needed to allow the encoded polypeptide to be produced in a cell. Expression cassettes can be exogenous (i.e., introduced into a cell) or endogenous (i.e., extant in a cell).
[032] As used herein, the terms "fused" and "fusion" with respect to two DNA
fragments, such as a promoter and the coding region of a polypeptide refer to a physical linkage causing the two DNA fragments to become a single molecule.
fragments, such as a promoter and the coding region of a polypeptide refer to a physical linkage causing the two DNA fragments to become a single molecule.
[033] As used herein, the terms "wild-type" and "native" are used interchangeably and refer to genes, proteins or strains found in nature, or that are not intentionally modified for the advantage of the presently described yeast.
[034] As used herein, the term "protein of interest" refers to a polypeptide that is desired to be expressed in modified yeast. Such a protein can be an enzyme, a substrate-binding protein, a surface-active protein, a structural protein, a selectable marker, or the like, and can be expressed. The protein of interest is encoded by an endogenous gene or a heterologous gene (i.e., gene of interest") relative to the parental strain. The protein of interest can be expressed intracellularly or as a secreted protein.
[035] As used herein, "disruption of a gene" refers broadly to any genetic or chemical manipulation, i.e., mutation, that substantially prevents a cell from producing a function gene product, e.g., a protein, in a host cell. Exemplary methods of disruption include complete or partial deletion of any portion of a gene, including a polypeptide-coding sequence, a promoter, an enhancer, or another regulatory element, or mutagenesis of the same, where mutagenesis encompasses substitutions, insertions, deletions, inversions, and combinations and variations, thereof, any of which mutations substantially prevent the production of a function gene product. A gene can also be disrupted using RNAi, antisense, or any other method that abolishes gene expression. A gene can be disrupted by deletion or genetic manipulation of non-adjacent control elements. As used herein, "deletion of a gene," refers to its removal from the genome of a host cell. Where a gene includes control elements (e.g., enhancer elements) that are not located immediately adjacent to the coding sequence of a gene, deletion of a gene refers to the deletion of the coding sequence, and optionally adjacent enhancer elements, including but not limited to, for example, promoter and/or terminator sequences, but does not require the deletion of non-adjacent control elements.
[036] As used herein, the terms "genetic manipulation" and "genetic alteration" are used interchangeably and refer to the alteration/change of a nucleic acid sequence.
The alteration can include but is not limited to a substitution, deletion, insertion or chemical modification of at least one nucleic acid in the nucleic acid sequence.
The alteration can include but is not limited to a substitution, deletion, insertion or chemical modification of at least one nucleic acid in the nucleic acid sequence.
[037] As used herein, a "functional polypeptide/protein" is a protein that possesses an activity, such as an enzymatic activity, a binding activity, a surface-active property, or the like, and which has not been mutagenized, truncated, or otherwise modified to abolish or reduce that activity. Functional polypeptides can be thermostable or thermolabile, as specified.
[038] As used herein, "a functional gene" is a gene capable of being used by cellular components to produce an active gene product, typically a protein. Functional genes are the antithesis of disrupted genes, which are modified such that they cannot be used by cellular components to produce an active gene product, or have a reduced ability to be used by cellular components to produce an active gene product.
[039] As used herein, yeast cells have been "modified to prevent the production of a specified protein" if they have been genetically or chemically altered to prevent the production of a functional protein/polypeptide that exhibits an activity characteristic of the wild-type protein. Such modifications include, but are not limited to, deletion or disruption of the gene encoding the protein (as described, herein), modification of the gene such that the encoded polypeptide lacks the aforementioned activity, modification of the gene to affect post-translational processing or stability, and combinations, thereof.
[040] As used herein, "attenuation of a pathway" or "attenuation of the flux through a pathway" i.e., a biochemical pathway, refers broadly to any genetic or chemical manipulation that reduces or completely stops the flux of biochemical substrates or intermediates through a metabolic pathway. Attenuation of a pathway may be achieved by a variety of well-known methods. Such methods include but are not limited to: complete or partial deletion of one or more genes, replacing wild-type alleles of these genes with mutant forms encoding enzymes with reduced catalytic activity or increased Km values, modifying the promoters or other regulatory elements that control the expression of one or more genes, engineering the enzymes or the mRNA encoding these enzymes for a decreased stability, misdirecting enzymes to cellular compartments where they are less likely to interact with substrate and intermediates, the use of interfering RNA, and the like.
[041] As used herein, "aerobic fermentation" refers to growth in the presence of oxygen.
[042] As used herein, "anaerobic fermentation" refers to growth in the absence of oxygen.
[043] As used herein, the expression "end of fermentation" refers to the stage of fermentation when the economic advantage of continuing fermentation to produce a small amount of additional alcohol is exceeded by the cost of continuing fermentation in terms of fixed and variable costs. In a more general sense, "end of fermentation"
refers to the point where a fermentation will no longer produce a significant amount of additional alcohol, i.e., no more than about 1% additional alcohol.
refers to the point where a fermentation will no longer produce a significant amount of additional alcohol, i.e., no more than about 1% additional alcohol.
[044] As used herein, the expression "carbon flux" refers to the rate of turnover of carbon molecules through a metabolic pathway. Carbon flux is regulated by enzymes involved in metabolic pathways, such as the pathway for glucose metabolism and the pathway for maltose metabolism.
[045] As used herein, the singular articles "a," "an" and "the" encompass the plural referents unless the context clearly dictates otherwise. All references cited herein are hereby incorporated by reference in their entirety. The following abbreviations/acronyms have the following meanings unless otherwise specified:
EC enzyme commission PKL phosphoketolase PTA phosphotransacetylase AADH acetaldehyde dehydrogenases ADH alcohol dehydrogenase Et0H ethanol AA a-amylase GA glucoamylase C degrees Centigrade bp base pairs DNA deoxyribonucleic acid ds or DS dry solids g or gm gram g/L grams per liter H20 water HPLC high performance liquid chromatography hr or h hour kg kilogram molar mg milligram mL or ml milliliter min minute mM millimolar normal nm nanometer PCR polymerase chain reaction ppm parts per million A relating to a deletion tg microgram [EL and 11.1 microliter micromolar II. Modified yeast harboring a constitutive MAL allele
EC enzyme commission PKL phosphoketolase PTA phosphotransacetylase AADH acetaldehyde dehydrogenases ADH alcohol dehydrogenase Et0H ethanol AA a-amylase GA glucoamylase C degrees Centigrade bp base pairs DNA deoxyribonucleic acid ds or DS dry solids g or gm gram g/L grams per liter H20 water HPLC high performance liquid chromatography hr or h hour kg kilogram molar mg milligram mL or ml milliliter min minute mM millimolar normal nm nanometer PCR polymerase chain reaction ppm parts per million A relating to a deletion tg microgram [EL and 11.1 microliter micromolar II. Modified yeast harboring a constitutive MAL allele
[046] The present inventors have discovered that modified yeast harboring a constitutive transcriptional activator MAL allele produces more ethanol in a starch-hydrolysate-fermentation, and/or produces the same amount of ethanol in less time, than an otherwise identical parental yeast. Remarkably, the additional ethanol produced does not appear to be the result, or at least solely the result, of maltose metabolism, as the small amount of maltose present in the starch hydrolysate remains basically unchanged following fermentation. Yeast harboring constitutive transcriptional activator MAL allele also produces ethanol at a higher rate in a starch-hydrolysate-fermentation than an otherwise identical parental yeast.
Therefore, the constitutive expression of the transcriptional activator MAL
allele appears to produce an unexpected benefit to glucose metabolism in a high-glucose environment.
Therefore, the constitutive expression of the transcriptional activator MAL
allele appears to produce an unexpected benefit to glucose metabolism in a high-glucose environment.
[047] The presence of a constitutive transcriptional activator MAL allele, optionally in the presence of other genetic modifications, results, in an increase in ethanol production, or rate of ethanol production, of at least 0.5%, at least 0.6%, at least 0.7%, at least 0.8%, at least 0.9%, at least 1.0%, at least 1.1%, at least 1.2%, or more. Although such an increase is modest, it amounts to a substantial increase in terms of volume, given the amount of ethanol currently being produced.
[048] The present yeast strains and methods are exemplified using a representative constitutive transcriptional activator M4L23 allele, shown as SEQ ID NO: 1, below:
MG IAKQS CDCCRVRRVKCDRNKPCNRC T QRNLNC TYLQPLKKRGPKS I RAGS LKK IAEVQMV
SMNNNIMTAPVVCKKVPKNL I DQCLRLYHDNLYVI WPMLSYDDLHKLLEENYEDCS TYWFLV
SLSAATLSDLQIE IEYEEGVT FTGEQLCTLCMLSRQFFDDLSNSDI FRIMTYYCLHRCYAQF
ADTRTSYRLSCEAIGL IKIAGFHREE TYE FLP FGEQQLRRKVYYLLLMTERFYAVY IKCVT S
LDTT IAPPLPEVVTDPRLSLES FLEVIRVFTVPGKCFYDALATNCVDDSCTEDSLKRIWNEL
HT T SLDIEPWSYGYVDI S FSRHWIRALAWKLVFQMNGTKFFSNANNAHILVE IAKDMLDDI F
L T PNNLYDVHGPG I PMKS LEVANALVD IVNKYDHNMKLEAWN I LCDVS KFVFS LKHCNHKMF
QRFS TKCQSAL I DLP I SRPLRLNDDSKDEDDI I P
MG IAKQS CDCCRVRRVKCDRNKPCNRC T QRNLNC TYLQPLKKRGPKS I RAGS LKK IAEVQMV
SMNNNIMTAPVVCKKVPKNL I DQCLRLYHDNLYVI WPMLSYDDLHKLLEENYEDCS TYWFLV
SLSAATLSDLQIE IEYEEGVT FTGEQLCTLCMLSRQFFDDLSNSDI FRIMTYYCLHRCYAQF
ADTRTSYRLSCEAIGL IKIAGFHREE TYE FLP FGEQQLRRKVYYLLLMTERFYAVY IKCVT S
LDTT IAPPLPEVVTDPRLSLES FLEVIRVFTVPGKCFYDALATNCVDDSCTEDSLKRIWNEL
HT T SLDIEPWSYGYVDI S FSRHWIRALAWKLVFQMNGTKFFSNANNAHILVE IAKDMLDDI F
L T PNNLYDVHGPG I PMKS LEVANALVD IVNKYDHNMKLEAWN I LCDVS KFVFS LKHCNHKMF
QRFS TKCQSAL I DLP I SRPLRLNDDSKDEDDI I P
[049] However, it is fully expected that the introduction of other constitutive transcriptional activator MAL alleles will produce similar results. Constitutive transcriptional activator MAL
alleles have been known for more than half-a-century, and are exemplified by those described in, e.g., Winge, 0. and Roberts, C. (1950) C. R. Tray. Lab. Carlsberg Ser.
Physiol. 25:35-81, Kahn, N.A. and Eaton, N.R. (1971)Mol. Gen. Genet. 112: 317-22; Charronm, J.
and Michels, C.A. (1987) Genetics 116 23-31; Zimmerman and Eaton, N.R. (1974)Mol. Gen.
Genet. 134 261-271; Rodicio, R. (1986) Curr. Genet. 11:235-41 and Ten Berge, A.M.A. et al. (1973) Mol. Gen. Genet. 125: 139-46, each of which references is incorporated by reference.
alleles have been known for more than half-a-century, and are exemplified by those described in, e.g., Winge, 0. and Roberts, C. (1950) C. R. Tray. Lab. Carlsberg Ser.
Physiol. 25:35-81, Kahn, N.A. and Eaton, N.R. (1971)Mol. Gen. Genet. 112: 317-22; Charronm, J.
and Michels, C.A. (1987) Genetics 116 23-31; Zimmerman and Eaton, N.R. (1974)Mol. Gen.
Genet. 134 261-271; Rodicio, R. (1986) Curr. Genet. 11:235-41 and Ten Berge, A.M.A. et al. (1973) Mol. Gen. Genet. 125: 139-46, each of which references is incorporated by reference.
[050] Yeast harboring constitutive transcriptional activator MAL alleles may also include other genetic manipulations that increase alcohol production, particularly modifications that are not associated with enhanced maltose metabolism.
III. Modified yeast harboring a constitutive MAL allele in combination with genes of an exogenous PKL pathway
III. Modified yeast harboring a constitutive MAL allele in combination with genes of an exogenous PKL pathway
[051] The presence of constitutive transcriptional activator MAL alleles can be combined with expression of genes in the PKL pathway to increase the growth rate of cells and further increase the production of ethanol.
[052] Engineered yeast cells having a heterologous PKL pathway have been previously described (e.g., W02015148272). These cells express heterologous PKL (EC
4.1.2.9) and PTA (EC 2.3.1.8), optionally with other enzymes, to channel carbon flux away from the glycerol pathway and toward the synthesis of acetyl-CoA, which is then converted to ethanol.
Such modified cells are capable of increased ethanol production in a fermentation process when compared to otherwise-identical parent yeast cells.
IV. Modified yeast harboring a constitutive MAL allele and having reduced D1s1 expression
4.1.2.9) and PTA (EC 2.3.1.8), optionally with other enzymes, to channel carbon flux away from the glycerol pathway and toward the synthesis of acetyl-CoA, which is then converted to ethanol.
Such modified cells are capable of increased ethanol production in a fermentation process when compared to otherwise-identical parent yeast cells.
IV. Modified yeast harboring a constitutive MAL allele and having reduced D1s1 expression
[053] D1s1, encoded by YJL065c, is a 167-amino acid polypeptide subunit of the yeast chromatin accessibility complex (yCHRAC), which contains Isw2, Itcl, Dpb3-like subunit (D1s1), and Dpb4 (see, e.g., Peterson, C.L. (1996) Curr. Op/n. Genet.
Dev. 6:171-75 and Winston, F. and Carlson, M. (1992) Trends Genet. 8:387-91). Yeast having a genetic alteration that reduces the amount of functional D1s1 in the cell, in the absence of other genetic modifications, exhibit increased robustness in an alcohol fermentation, allowing higher-temperature, and potentially shorter, fermentations (data not shown).
Dev. 6:171-75 and Winston, F. and Carlson, M. (1992) Trends Genet. 8:387-91). Yeast having a genetic alteration that reduces the amount of functional D1s1 in the cell, in the absence of other genetic modifications, exhibit increased robustness in an alcohol fermentation, allowing higher-temperature, and potentially shorter, fermentations (data not shown).
[054] Reduction in the amount of functional D1s1 produced in a cell can be accomplished by disruption of the YA065c gene. Disruption of the YA065c gene can be performed using any suitable methods that substantially prevent expression of a function Y.IL065c gene product, i.e., D1s1. Exemplary methods of disruption as are known to one of skill in the art include but are not limited to: complete or partial deletion of the Y.IL065c gene, including complete or partial deletion of, e.g., the Dlsl-coding sequence, the promoter, the terminator, an enhancer, or another regulatory element; and complete or partial deletion of a portion of the chromosome that includes any portion of the YJL065c gene.
[055] Particular methods of disrupting the Y.IL065c gene include making nucleotide substitutions or insertions in any portion of the Y.IL065c gene, e.g., the Dlsl-coding sequence, the promoter, the terminator, an enhancer, or another regulatory element.
Preferably, deletions, insertions, and/or substitutions (collectively referred to as mutations) are made by genetic manipulation using sequence-specific molecular biology techniques, as opposed to by chemical mutagenesis, which is generally not targeted to specific nucleic acid sequences.
Nonetheless, chemical mutagenesis can, in theory, be used to disrupt the Y.IL065c gene.
V. Additional mutations that affect alcohol production
Preferably, deletions, insertions, and/or substitutions (collectively referred to as mutations) are made by genetic manipulation using sequence-specific molecular biology techniques, as opposed to by chemical mutagenesis, which is generally not targeted to specific nucleic acid sequences.
Nonetheless, chemical mutagenesis can, in theory, be used to disrupt the Y.IL065c gene.
V. Additional mutations that affect alcohol production
[056] The present modified yeast may further include, or may expressly exclude, mutations that result in attenuation of the native glycerol biosynthesis pathway, which are known to increase alcohol production. Methods for attenuation of the glycerol biosynthesis pathway in yeast are known and include reduction or elimination of endogenous NAD-dependent glycerol 3-phosphate dehydrogenase (GPD) or glycerol phosphate phosphatase activity (GPP), for example by disruption of one or more of the genes GPD1, GPD2, GPP 1 and/or GPP2. See, e.g., U.S. Patent Nos. 9,175,270 (Elke et al.), 8,795,998 (Pronk et al.) and 8,956,851 (Argyros et al.).
[057] The modified yeast may further feature increased acetyl-CoA synthase (also referred to acetyl-CoA ligase) activity (EC 6.2.1.1) to scavenge (i.e., capture) acetate produced by chemical or enzymatic hydrolysis of acetyl-phosphate (or present in the culture medium of the yeast for any other reason) and converts it to acetyl-CoA. This avoids the undesirable effect of acetate on the growth of yeast cells and may further contribute to an improvement in alcohol yield. Increasing acetyl-CoA synthase activity may be accomplished by introducing a heterologous acetyl-CoA synthase gene into cells, increasing the expression of an endogenous acetyl-CoA synthase gene and the like. A particularly useful acetyl-CoA
synthase for introduction into cells can be obtained from Methanosaeta concilii (UniProt/TrEMBL Accession No.: WPO13718460). Homologs of this enzymes, including enzymes having at least 85%, at least 90%, at least 92%, at least 95%, at least 97%, at least 98% and even at least 99% amino acid sequence identity to the aforementioned acetyl-CoA
synthase from Methanosaeta concilii, are also useful in the present compositions and methods. In other embodiments, the present modified yeast do not have increased acetyl-CoA synthase.
synthase for introduction into cells can be obtained from Methanosaeta concilii (UniProt/TrEMBL Accession No.: WPO13718460). Homologs of this enzymes, including enzymes having at least 85%, at least 90%, at least 92%, at least 95%, at least 97%, at least 98% and even at least 99% amino acid sequence identity to the aforementioned acetyl-CoA
synthase from Methanosaeta concilii, are also useful in the present compositions and methods. In other embodiments, the present modified yeast do not have increased acetyl-CoA synthase.
[058] In some embodiments the present modified yeast may further include a heterologous gene encoding a protein with NAD+-dependent acetylating acetaldehyde dehydrogenase activity and/or a heterologous gene encoding a pyruvate-formate lyase. The introduction of such genes in combination with attenuation of the glycerol pathway is described, e.g., in U.S.
Patent No. 8,795,998 (Pronk et al.). However, in most embodiments of the present compositions and methods, the introduction of an acetylating acetaldehyde dehydrogenase and/or a pyruvate-formate lyase is not required because the need for these activities is obviated by the attenuation of the native biosynthetic pathway for making acetyl-CoA that contributes to redox cofactor imbalance. Accordingly, in some embodiments, the present yeast do not have a heterologous gene encoding an NAD+-dependent acetylating acetaldehyde dehydrogenase and/or encoding a pyruvate-formate lyase.
Patent No. 8,795,998 (Pronk et al.). However, in most embodiments of the present compositions and methods, the introduction of an acetylating acetaldehyde dehydrogenase and/or a pyruvate-formate lyase is not required because the need for these activities is obviated by the attenuation of the native biosynthetic pathway for making acetyl-CoA that contributes to redox cofactor imbalance. Accordingly, in some embodiments, the present yeast do not have a heterologous gene encoding an NAD+-dependent acetylating acetaldehyde dehydrogenase and/or encoding a pyruvate-formate lyase.
[059] In some embodiments, the present modified yeast further comprises a butanol biosynthetic pathway. In some embodiments, the butanol biosynthetic pathway is an isobutanol biosynthetic pathway. The isobutanol biosynthetic pathway may comprise a polynucleotide encoding a polypeptide that catalyzes a substrate to product conversion selected from the group consisting of: (a) pyruvate to acetolactate; (b) acetolactate to 2,3-dihydroxyisovalerate; (c) 2,3-dihydroxyisovalerate to 2-ketoisovalerate; (d) 2-ketoisovalerate to isobutyraldehyde; and (e) isobutyraldehyde to isobutanol. The isobutanol biosynthetic pathway may comprise polynucleotides encoding polypeptides having acetolactate synthase, keto acid reductoisomerase, dihydroxy acid dehydratase, ketoisovalerate decarboxylase, and alcohol dehydrogenase activity.
[060] In some embodiments, the modified yeast comprising a butanol biosynthetic pathway further comprise a modification in a polynucleotide encoding a polypeptide having pyruvate decarboxylase activity. The yeast may comprise a deletion, mutation, and/or substitution in an endogenous polynucleotide encoding a polypeptide having pyruvate decarboxylase activity. In some embodiments, the polypeptide having pyruvate decarboxylase activity is selected from the group consisting of: PDC1, PDC5, PDC6, and combinations thereof. In some embodiments, the yeast cells further comprise a deletion, mutation, and/or substitution in one or more endogenous polynucleotides encoding FRA2, ALD6, ADH1, GPD2, BDH1, and Y1V1R226C. In other embodiments, the present modified yeast cells do not further comprise a butanol biosynthetic pathway.
[061] The present modified yeast may include any number of additional genes of interest encoding protein of interest, including selectable markers, carbohydrate-processing enzymes, and other commercially-relevant polypeptides, including but not limited to an enzyme selected from the group consisting of a dehydrogenase, a transketolase, a phosphoketolase, a transladolase, an epimerase, a phytase, a xylanase, a 0-glucanase, a phosphatase, a protease, an a-amylase, a 0-amylase, a glucoamylase, a pullulanase, an isoamylase, a cellulase, a trehalase, a lipase, a pectinase, a polyesterase, a cutinase, an oxidase, a transferase, a reductase, a hemicellulase, a mannanase, an esterase, an isomerase, a pectinases, a lactase, a peroxidase and a laccase. Proteins of interest may be secreted, glycosylated, and otherwise modified.
VI. Use of the modified yeast for increased alcohol production
VI. Use of the modified yeast for increased alcohol production
[062] The present yeast, and methods of use, thereof, include methods for increasing alcohol production in fermentation reactions. Such methods are not limited to a particular fermentation process. The present engineered yeast is expected to be a "drop-in" replacement for convention yeast in any alcohol fermentation facility. While primarily intended for fuel ethanol production, the present yeast can also be used for the production of potable alcohol, including wine and beer.
VII. Yeast suitable for modification
VII. Yeast suitable for modification
[063] Yeast is a unicellular eukaryotic microorganism classified as members of the fungus kingdom and includes organisms from the phyla Ascomycota and Basidiomycota.
Yeast that can be used for alcohol production include, but are not limited to, Saccharomyces spp., including S. cerevisiae, as well as Kluyveromyces, Lachancea and Schizosaccharomyces spp.
Numerous yeast strains are commercially available, many of which have been selected or genetically engineered for desired characteristics, such as high alcohol production, rapid growth rate, and the like. Some yeast has been genetically engineered to produce heterologous enzymes, such as glucoamylase or a-amylase.
VIII. Substrates and products
Yeast that can be used for alcohol production include, but are not limited to, Saccharomyces spp., including S. cerevisiae, as well as Kluyveromyces, Lachancea and Schizosaccharomyces spp.
Numerous yeast strains are commercially available, many of which have been selected or genetically engineered for desired characteristics, such as high alcohol production, rapid growth rate, and the like. Some yeast has been genetically engineered to produce heterologous enzymes, such as glucoamylase or a-amylase.
VIII. Substrates and products
[064] Alcohol production from a number of carbohydrate substrates, including but not limited to corn starch, sugar cane, cassava, and molasses, is well known, as are innumerable variations and improvements to enzymatic and chemical conditions and mechanical processes. The present compositions and methods are believed to be fully compatible with such substrates and conditions. High levels of maltose are not required to benefit from the present compositions and methods. In some embodiments, the concentration is less than about 10 g/L.
[065] These and other aspects and embodiments of the present strains and methods will be apparent to the skilled person in view of the present description. The following examples are intended to further illustrate, but not limit, the strains and methods.
EXAMPLES
Example 1 Materials and methods Liquefact preparation:
EXAMPLES
Example 1 Materials and methods Liquefact preparation:
[066] Liquefact (corn mash slurry) was prepared by adding 600 ppm of urea, 0.124 SAPU/g ds FERMGENTm 2.5x (acid fungal protease), 0.33 GAU/g ds CS4 (a variant Trichoderma glucoamylase) and 1.46 SSCU/g ds AKAA (Aspergillus kawachii a-amylase), adjusted to a pH of 4.8.
Serum vial assays:
Serum vial assays:
[067] 2 mL of YPD in 24-well plates were inoculated with yeast cells and the cultures allowed to grow overnight to an OD between 25-30. 2.5 mL liquefact was transferred to serum vials (Chemglass, Catalog #: CG-4904-01) and yeast was added to each vial to a final OD of about 0.4-0.6. The lids of the vials were installed and punctured with needle (BD, Catalog #305111) for ventilation (to release CO2), then incubated at 32 C with shaking at 200 RPM for 65 hours.
AnKom assays:
AnKom assays:
[068] 300 L of concentrated yeast overnight culture was added to each of a number ANKOM bottles filled with 50 g prepared liquefact (see above) to a final OD of 0.3. The bottles were then incubated at 32 C with shaking at 150 RPM for 65 hours.
HPLC analysis:
HPLC analysis:
[069] Samples of the cultures from serum vials and AnKom assays were collected in Eppendorf tubes by centrifugation for 12 minutes at 14,000 RPM. The supernatants were filtered using 0.2 M PTFE filters and then used for HPLC (Agilent Technologies 1200 series) analysis with the following conditions: Bio-Rad Aminex HPX-87H
columns, running temperature of 55C. 0.6 ml/min isocratic flow 0.01 N H2504, 2.5 1 injection volume.
Calibration standards were used for quantification of the of acetate, ethanol, glycerol, glucose and other molecules. All values are reported in g/L.
Example 2 Preparation of a constitutive MAL23 allele cassette
columns, running temperature of 55C. 0.6 ml/min isocratic flow 0.01 N H2504, 2.5 1 injection volume.
Calibration standards were used for quantification of the of acetate, ethanol, glycerol, glucose and other molecules. All values are reported in g/L.
Example 2 Preparation of a constitutive MAL23 allele cassette
[070] A MAL23c expression cassette, consisting of a constitutive allele of MAL23 (SEQ ID
NO: 2) under control of a MAL23c promoter (SEQ ID NO: 3) and MAL23 terminator (SEQ
ID NO: 4), was made using standard procedures. The nucleotide sequences are shown, below, and a representation of the cassette is illustrated in Figure 2:
DNA coding region of the constitutive MAL23 allele (SEQ ID NO: 2):
ATGGGTATTGCGAAACAGTCTTGCGACTGCTGTCGCGTTCGTCGAGTAAAGTGTGACAGGAA
TAAACCATGTAATCGCTGCACTCAGCGCAATTTGAACTGCACTTATCTTCAACCGTTGAAAA
AGAGAGGTCCAATCCAT TAGAGCAGGGCT TAATAGCGGAGTGCAGATGGTG
AGTATGAATAATAATATTATGACCGCTCCGGTGGTATGTAAGAAGGTTCCGAAAAACCTGAT
TGATCAATGTTTGAGGTTGTATCATGATAACTTATATGTAATTTGGCCAATGCTTTCCTACG
ATGATCTTCACAAGCTTTTGGAGGAAAATTATGAGGACTGCAGCACTTATTGGTTTCTGGTA
TCCCTTTCGGCAGCTACTCTTAGCGACTTGCAAATTGAAATAGAGTATGAGGAAGGAGTCAC
TTTTACTGGAGAGCAGTTATGCACTCTTTGCATGTTATCTCGGCAATTCTTTGACGACCTTA
GTAACAGCGACATAT TTCGAATCATGACATACTAT TGT TTGCACCGT TGT TACGCGCAGT TT
GCTGATACAAGAACTTCATACAGACTTTCTTGTGAGGCTATTGGCCTCATCAAGATAGCTGG
ATTCCATCGGGAAGAAACCTATGAATICCTICCCTICGGTGAACAACAACICAGAAGGAAAG
TTTACTATTTACTTCTTATGACAGAGAGATTTTACGCTGTATATATTAAGTGTGTCACGAGC
CTAGATACAACAATAGCGCCACCACTACCAGAGGTTGTAACAGACCCTCGTCTTTCTCTGGA
AAGCTTCCTTGAGGTGATTAGAGTTTTCACTGTACCTGGAAAGTGTTTTTATGATGCTTTGG
CTACTAACTGTGTCGATGATICCTGCACCGAAGACTCTCTAAAAAGGATATGGAACGAACTI
CATACCACATCACTTGATATAGAGCCATGGTCTTATGGCTATGTGGACATTTCATTTTCTCG
ACATTGGATTAGGGCGCTGGCTTGGAAGCTAGTGTTTCAGATGAATGGTACCAAGTTTTTCT
CAAACGCCAATAATGCTCACATATTGGTCGAAATTGCAAAGGATATGCTGGACGACATATTC
TTAACTCCAAACAACCTGTATGATGTACATGGTCCTGGAATACCAATGAAATCATTGGAAGT
AGCCAATGCATTGGTAGATATCGTAAATAAGTATGATCACAATATGAAGTTGGAGGCTTGGA
ATATTTTGTGCGATGTATCCAAGTTCGTTTTCTCCCTGAAACATTGCAATCATAAAATGTTT
CAAAGGITTICAACTAAATGICAGAGTGCTCTAATCGATTIGCCTATCTCTAGACCACTGCG
CCTAAATGATGATTCCAAAGATGAAGACGACATAATTCCTTAA
DNA sequence of the MAL23c promoter (SEQ ID NO: 3):
TATTGTCCGTTCCATTGTATTCAATAACTTAAATGCAACAGAAAATGATTACAGGATTCTTC
TCTCATAGAAATATAAGCAAACT T CAAAT GGAAC T GAGA AATTTCCTTTCTATTGGA
ATTTTACTTTACAAATGACTTTGGCAAAACAGGCATGCGATTGTTGTCGTGTTCGTCGAGTA
AAGTGTGACGGCGAAAAGCCATGTAATCGT TGTCTGCAGCATGAT TTGAAATGTACT TAT TT
ACAACCTTTGAGAAAAAGAGGGCCCAAAAATATTAGATCGAGAAGTTTAAAGAAAATTGCCG
AAACGCAAACGTTCAGTGAGAACAACAACTGTATGACAGCTTTAGAAATATCTATAGGAATC
ATTATATCTTACATGTTATTCTGTTCTGTTGTAGTAACTAATTTCAGAGATCTTTTCGGATG
CTACTACCCCTGTTTATAACGTGTAACTTTAATCTTGAAATTTCGTTTTTTCCCCACAATTT
TTCCGTAGCCTTTCTCGCGAGAATTAATCCGTCGTACAATAATTCGATCTTACTTGTATTTT
CTCCCATGAGCATGCAGACTAATAGGTAGGAAAATAGAACTACTTAGAAACATTCTCCT TAA
GTGTTTTCACCACTAAGCATTTTATATTTAATTGTTAAAAAATATATACTATTGAAGAACCA
CTTTCCTGAAATATCAAGAACAAAAAAGTCTGCACTATGGTCCCGCAATTGATGCATTTGAG
AATTCTTTTAACTCAATAGTAATATGCATTGTTCTTATCTAAAAAATTGCAGGTACCTGCAG
ACTAATCCGGGTCATGATCTGCGCTGCGCCGTCATCCCACCCCGTGCTGCCTGCCACTTGAA
GCTACCCGGGTTTAATAATTCGTTCTTAAGTTCTACAACTTAAATACAGGCAGCTAAAAAAC
TGGGTTCGAGAGTTTTCCACTTTATAGACAAAAATAAAAATACTGCCAGAAAATTTATCATA
TAATAAT
DNA sequence of the MAL23c terminator (SEQ ID NO: 4):
TTTATTGTTCACGCCGTTCACTTATACGAGATAGATATACTGATAGAGTGTGAGTGATATTC
TTAAGTCTTGCTTTTCGAGGGTGTAAGAAGCTATGTTCTTCAGGCGAGATTATTCTACTCCT
GCCTTACTTGTTTGTAATATTTAGTTCTGATGGTCATGATAATTCTATATACAGTTACAT TA
AGTATATACTTAAGCGGGCAGCTTACTAATATAAATTTTGTGGCATTTTTGTTGGGATATGA
GAATCATGTATCGTTGATTTACAAAGCGAATTTACGTTACCAGGAATAGGGAA
NO: 2) under control of a MAL23c promoter (SEQ ID NO: 3) and MAL23 terminator (SEQ
ID NO: 4), was made using standard procedures. The nucleotide sequences are shown, below, and a representation of the cassette is illustrated in Figure 2:
DNA coding region of the constitutive MAL23 allele (SEQ ID NO: 2):
ATGGGTATTGCGAAACAGTCTTGCGACTGCTGTCGCGTTCGTCGAGTAAAGTGTGACAGGAA
TAAACCATGTAATCGCTGCACTCAGCGCAATTTGAACTGCACTTATCTTCAACCGTTGAAAA
AGAGAGGTCCAATCCAT TAGAGCAGGGCT TAATAGCGGAGTGCAGATGGTG
AGTATGAATAATAATATTATGACCGCTCCGGTGGTATGTAAGAAGGTTCCGAAAAACCTGAT
TGATCAATGTTTGAGGTTGTATCATGATAACTTATATGTAATTTGGCCAATGCTTTCCTACG
ATGATCTTCACAAGCTTTTGGAGGAAAATTATGAGGACTGCAGCACTTATTGGTTTCTGGTA
TCCCTTTCGGCAGCTACTCTTAGCGACTTGCAAATTGAAATAGAGTATGAGGAAGGAGTCAC
TTTTACTGGAGAGCAGTTATGCACTCTTTGCATGTTATCTCGGCAATTCTTTGACGACCTTA
GTAACAGCGACATAT TTCGAATCATGACATACTAT TGT TTGCACCGT TGT TACGCGCAGT TT
GCTGATACAAGAACTTCATACAGACTTTCTTGTGAGGCTATTGGCCTCATCAAGATAGCTGG
ATTCCATCGGGAAGAAACCTATGAATICCTICCCTICGGTGAACAACAACICAGAAGGAAAG
TTTACTATTTACTTCTTATGACAGAGAGATTTTACGCTGTATATATTAAGTGTGTCACGAGC
CTAGATACAACAATAGCGCCACCACTACCAGAGGTTGTAACAGACCCTCGTCTTTCTCTGGA
AAGCTTCCTTGAGGTGATTAGAGTTTTCACTGTACCTGGAAAGTGTTTTTATGATGCTTTGG
CTACTAACTGTGTCGATGATICCTGCACCGAAGACTCTCTAAAAAGGATATGGAACGAACTI
CATACCACATCACTTGATATAGAGCCATGGTCTTATGGCTATGTGGACATTTCATTTTCTCG
ACATTGGATTAGGGCGCTGGCTTGGAAGCTAGTGTTTCAGATGAATGGTACCAAGTTTTTCT
CAAACGCCAATAATGCTCACATATTGGTCGAAATTGCAAAGGATATGCTGGACGACATATTC
TTAACTCCAAACAACCTGTATGATGTACATGGTCCTGGAATACCAATGAAATCATTGGAAGT
AGCCAATGCATTGGTAGATATCGTAAATAAGTATGATCACAATATGAAGTTGGAGGCTTGGA
ATATTTTGTGCGATGTATCCAAGTTCGTTTTCTCCCTGAAACATTGCAATCATAAAATGTTT
CAAAGGITTICAACTAAATGICAGAGTGCTCTAATCGATTIGCCTATCTCTAGACCACTGCG
CCTAAATGATGATTCCAAAGATGAAGACGACATAATTCCTTAA
DNA sequence of the MAL23c promoter (SEQ ID NO: 3):
TATTGTCCGTTCCATTGTATTCAATAACTTAAATGCAACAGAAAATGATTACAGGATTCTTC
TCTCATAGAAATATAAGCAAACT T CAAAT GGAAC T GAGA AATTTCCTTTCTATTGGA
ATTTTACTTTACAAATGACTTTGGCAAAACAGGCATGCGATTGTTGTCGTGTTCGTCGAGTA
AAGTGTGACGGCGAAAAGCCATGTAATCGT TGTCTGCAGCATGAT TTGAAATGTACT TAT TT
ACAACCTTTGAGAAAAAGAGGGCCCAAAAATATTAGATCGAGAAGTTTAAAGAAAATTGCCG
AAACGCAAACGTTCAGTGAGAACAACAACTGTATGACAGCTTTAGAAATATCTATAGGAATC
ATTATATCTTACATGTTATTCTGTTCTGTTGTAGTAACTAATTTCAGAGATCTTTTCGGATG
CTACTACCCCTGTTTATAACGTGTAACTTTAATCTTGAAATTTCGTTTTTTCCCCACAATTT
TTCCGTAGCCTTTCTCGCGAGAATTAATCCGTCGTACAATAATTCGATCTTACTTGTATTTT
CTCCCATGAGCATGCAGACTAATAGGTAGGAAAATAGAACTACTTAGAAACATTCTCCT TAA
GTGTTTTCACCACTAAGCATTTTATATTTAATTGTTAAAAAATATATACTATTGAAGAACCA
CTTTCCTGAAATATCAAGAACAAAAAAGTCTGCACTATGGTCCCGCAATTGATGCATTTGAG
AATTCTTTTAACTCAATAGTAATATGCATTGTTCTTATCTAAAAAATTGCAGGTACCTGCAG
ACTAATCCGGGTCATGATCTGCGCTGCGCCGTCATCCCACCCCGTGCTGCCTGCCACTTGAA
GCTACCCGGGTTTAATAATTCGTTCTTAAGTTCTACAACTTAAATACAGGCAGCTAAAAAAC
TGGGTTCGAGAGTTTTCCACTTTATAGACAAAAATAAAAATACTGCCAGAAAATTTATCATA
TAATAAT
DNA sequence of the MAL23c terminator (SEQ ID NO: 4):
TTTATTGTTCACGCCGTTCACTTATACGAGATAGATATACTGATAGAGTGTGAGTGATATTC
TTAAGTCTTGCTTTTCGAGGGTGTAAGAAGCTATGTTCTTCAGGCGAGATTATTCTACTCCT
GCCTTACTTGTTTGTAATATTTAGTTCTGATGGTCATGATAATTCTATATACAGTTACAT TA
AGTATATACTTAAGCGGGCAGCTTACTAATATAAATTTTGTGGCATTTTTGTTGGGATATGA
GAATCATGTATCGTTGATTTACAAAGCGAATTTACGTTACCAGGAATAGGGAA
[071] A DNA fragment including flanking YDL227C locus sequences was made by amplifying the MAL23c expression cassette with appropriate primers. The fragment was inserted into a plasmid designated pHX19, whichincludes an integrated constitutive MAL23c expression cassette at the Saccharomyces chromosome YDL227C locus, as shown in Figure 3. The functional and structural composition of plasmid pHX19 is described in Table 1.
Table 1. Functional and structural elements of plasmid pHX19 Functional/structural element Description 5' HO Arm fragment of YDL227C 293-bp DNA fragment from S. cerevisiae locus 3' HO Arm fragment of YDL227C 290-bp DNA fragment from S. cerevisiae locus ColE1 replicon, ampicillin Sequences not to be integrated into a yeast genome resistance marker gene, Fl origin of replication, CEN6, ARSH4, His Promoter, His coding region, and His terminator Ma123p::MAL23::MAL23t MAL23c expression cassette Example 3 Generation of yeast with a MAL23c expression cassette
Table 1. Functional and structural elements of plasmid pHX19 Functional/structural element Description 5' HO Arm fragment of YDL227C 293-bp DNA fragment from S. cerevisiae locus 3' HO Arm fragment of YDL227C 290-bp DNA fragment from S. cerevisiae locus ColE1 replicon, ampicillin Sequences not to be integrated into a yeast genome resistance marker gene, Fl origin of replication, CEN6, ARSH4, His Promoter, His coding region, and His terminator Ma123p::MAL23::MAL23t MAL23c expression cassette Example 3 Generation of yeast with a MAL23c expression cassette
[072] To study the effects of MAL23c in industrial yeast, the wild-type FERMAXTm Gold strain (Martrex, Inc., Chaska, MN, USA), hereafter abbreviated, "FG," was used as a parent to introduce the MAL23c expression cassette at the YDL227C integration site.
Cells were transformed with a 3,362-bp, PCR-amplified DNA fragment using appropriate flanking primers and PFIX 1 plasmid as template. Transformants were selected and a representative member was designated strain A28.
Example 4 Comparison of FG yeast with or without MAL23c
Cells were transformed with a 3,362-bp, PCR-amplified DNA fragment using appropriate flanking primers and PFIX 1 plasmid as template. Transformants were selected and a representative member was designated strain A28.
Example 4 Comparison of FG yeast with or without MAL23c
[073] Strain A28, and parental strain FG, were grown in Ankom bottles and their fermentation products analyzed as described in Example 1. Performance in terms of cumulative CO2 pressure index (CPI), indication of the fermentation rate, is shown in Figure 4. The performance in terms of ethanol, glycerol and acetate production is shown in Table 2.
Table 2. FG versus A28 in AnKom assay Increase in Strain Maltotriose Maltose Glucose Glycerol Acetate Ethanol Ethanol FG 2.22 6.90 13.49 17.78 0.91 134.03 A28 2.21 6.86 13.96 17.55 0.88 135.48 1.1%
Table 2. FG versus A28 in AnKom assay Increase in Strain Maltotriose Maltose Glucose Glycerol Acetate Ethanol Ethanol FG 2.22 6.90 13.49 17.78 0.91 134.03 A28 2.21 6.86 13.96 17.55 0.88 135.48 1.1%
[074] The performance of the FG parent and strain A28 is similar in terms of the residual amounts of maltotriose, maltose, and glucose, suggesting that the integration of the MAL23c DNA fragment at the YDL227C locus did not affect the maltose metabolism in the glucose based corn mash fermentation. The ethanol titer of the Ma123c expressing strain is higher than the FG control by 1.1%. The CPI data in Figure 4 demonstrates that the fermentation rate of strain A28 is also higher than parent FG strain. The experiment was repeated and the results confirmed.
Example 5 Generation of a plasmid containing a complete PKL pathway
Example 5 Generation of a plasmid containing a complete PKL pathway
[075] Plasmid pZKAP1m-(H3C19) was designed to integrate four individual polypeptide expression cassettes upstream of the AAP1 locus (YHR047C). The four cassettes were as follows (i) HXT3 promoter: :PKL C::FBA1 terminator; (ii) PGKlpromoter::LpPTA::PGK1 terminator; (iii) TDH3 promoter::eutE A19::ENO terminator; and (iv) PDC1 promoter::AcsAl ::PDC1 terminator, which were designed to express codon-optimized genes encoding phosphoketolase (PKL), derived from Gardnerella vaginalis, phosphotransacetylase (PTA), derived from Lactobacillus plantarum; acylating acetaldehyde dehydrogenase, derived from Desulfospira joergensenii, and acetyl-CoA
synthase, derived from Methanosaeta concilii, respectively. A map of pZKAP1m-(H3C19) is shown in Figure 5. Functional and structural elements are detailed in Table 3.
synthase, derived from Methanosaeta concilii, respectively. A map of pZKAP1m-(H3C19) is shown in Figure 5. Functional and structural elements are detailed in Table 3.
[076] Table 3. Functional and structural elements of construct pZKAP1m-(H3C19) Functional/structural Description element AAP1-C 522-bp fragment, upstream of AAP 1 LoxP71 LoxP71 site URA3 URA3 gene used as selection marker LoxP66 LoxP66 site AAP1-D 476-bp fragment, upstream of AAP 1 ORI and AP Replication origin and ampicillin resistance gene, these sequences are not part of the DNA fragment integrated into yeast genome AAP1-U 465-bp fragment, upstream of AAP]
PDC1 promoter S. cerevisiae PDC1 promoter X4 Mathanosaeta CDS encoding acetyl-CoA synthase from Methanosaeta concilii acsAl cons/iii, codon-optimized for yeast PDC1 terminator S. cerevisiae PDC1 transcription terminator TDH3 promoter S. cerevisiae TDH3 promoter eutE A19 CDS encoding acylating acetaldehyde dehydrogenase from Desulfospira joergensenii , codon-optimized for yeast EN02 terminator S. cerevisiae EN02 transcription terminator PGK1 promoter S. cerevisiae PGK1 promoter L. plantarum PTA CDS encoding phosphotransacetylase from Lactobacillus plantarum, codon-optimized for yeast PGK1 transcription S. cerevisiae pGK1 transcription terminator terminator HXT3 promoter S. cerevisiae HXT3 promoter PKL C CDS encoding phosphoketolase from Gardnerella vaginalis, codon-optimized for yeast FBA 1 terminator S. cerevisiae FBA1 transcription terminator Example 6 Generation of FG-ura3 yeast
PDC1 promoter S. cerevisiae PDC1 promoter X4 Mathanosaeta CDS encoding acetyl-CoA synthase from Methanosaeta concilii acsAl cons/iii, codon-optimized for yeast PDC1 terminator S. cerevisiae PDC1 transcription terminator TDH3 promoter S. cerevisiae TDH3 promoter eutE A19 CDS encoding acylating acetaldehyde dehydrogenase from Desulfospira joergensenii , codon-optimized for yeast EN02 terminator S. cerevisiae EN02 transcription terminator PGK1 promoter S. cerevisiae PGK1 promoter L. plantarum PTA CDS encoding phosphotransacetylase from Lactobacillus plantarum, codon-optimized for yeast PGK1 transcription S. cerevisiae pGK1 transcription terminator terminator HXT3 promoter S. cerevisiae HXT3 promoter PKL C CDS encoding phosphoketolase from Gardnerella vaginalis, codon-optimized for yeast FBA 1 terminator S. cerevisiae FBA1 transcription terminator Example 6 Generation of FG-ura3 yeast
[077] The FG strain was used as the parent strain to make the ura3 auxotrophic strain FG-ura3.
Plasmid pTOPO II-Blunt ura3-loxP-KanMX-loxP-ura3, depicted in Figure 6, was designed to replace the URA3 gene in strain FG with mutated ura3 and URA3-loxP-TEFp-KanMX-TEFt-loxP-URA3 fragment. The functional and structural elements of the plasmid are listed in Table 4.
Table 4. Functional/structural elements of pTOPO II-Blunt ura3-loxP-KanMX-loxP-ura3 Functional/Structural Element Description KanR gene in E. coil Vector sequence pUC origin Vector sequence UR43 3'-flanking region Synthetic DNA identical to S. cerevisiae genomic sequence to URA3 locus loxP66 Synthetic DNA identical to loxP66 consensus TEF1::KanMX4::TEF terminator KanMX expression cassette loxP71 Synthetic DNA identical to loxP71 consensus URA3 5'-flanking region Synthetic DNA identical to the URA3 locus on the S. cerevisiae genome
Plasmid pTOPO II-Blunt ura3-loxP-KanMX-loxP-ura3, depicted in Figure 6, was designed to replace the URA3 gene in strain FG with mutated ura3 and URA3-loxP-TEFp-KanMX-TEFt-loxP-URA3 fragment. The functional and structural elements of the plasmid are listed in Table 4.
Table 4. Functional/structural elements of pTOPO II-Blunt ura3-loxP-KanMX-loxP-ura3 Functional/Structural Element Description KanR gene in E. coil Vector sequence pUC origin Vector sequence UR43 3'-flanking region Synthetic DNA identical to S. cerevisiae genomic sequence to URA3 locus loxP66 Synthetic DNA identical to loxP66 consensus TEF1::KanMX4::TEF terminator KanMX expression cassette loxP71 Synthetic DNA identical to loxP71 consensus URA3 5'-flanking region Synthetic DNA identical to the URA3 locus on the S. cerevisiae genome
[078] A 2,018-bp DNA fragment containing the ura3-loxP-KanMX-loxP-ura3 cassette was released from plasmid TOPO II-Blunt ura3-loxP-KanMX-loxP-ura3 by EcoRI
digestion. The fragment was used to transform S. cerevisiae FG cells by electroporation.
digestion. The fragment was used to transform S. cerevisiae FG cells by electroporation.
[079] Transformed colonies able to grow on media containing G418 were streaked on synthetic minimal plates containing 20 i.tg/mluracil and 2 mg/ml 5-fluoroorotic acid (5-FOA). Colonies able to grow on 5-FOA plates were further confirmed for URA3 deletion by growth of phenotype on SD-Ura plates, and by PCR. The ura3 deletion transformants were unable to grow on SD-Ura plates. A single 1.98-kb PCR fragment was obtained with test primers. In contrast, the same primer pairs generated a 1.3-kb fragment using DNA from the parental FG strain, indicating the presence of the intact ura3 gene. The ura3 deletion strain was named as FG-KanMX-ura3.
[080] To remove the KanMX expression cassette from strain FG-KanMX-ura3, plasmid pGAL-Cre-316, depicted in Figure 7, was used to transform cells of strain FG-KanMX-ura3 by electroporation. The purpose of using this plasmid is to temporary express the Cre enzyme, so that the LoxP-sandwiched KanMX gene will be removed from strain FG-KanMX-ura3 to generate strain FG-ura3. pGAL-Cre-316 is a self-replicating circular plasmid that was subsequently removed from strain FG-ura3. None of the sequence elements from pGAL-cre-316 was inserted into the strain FG-ura3 genome. The functional and structural elements of plasmid pGAL-Cre-316 is listed in Table 5.
Table 5. Functional and structural elements of pGAL-Cre-316.
Functional/structural element Yeast-bacterial shuttle vector pRS316 sequence pBR322 origin of replication S. cerevisiae URA3 gene Fl origin GALp-Cre-ADHt cassette, reverse orientation
Table 5. Functional and structural elements of pGAL-Cre-316.
Functional/structural element Yeast-bacterial shuttle vector pRS316 sequence pBR322 origin of replication S. cerevisiae URA3 gene Fl origin GALp-Cre-ADHt cassette, reverse orientation
[081] The transformed cells were plated on SD-Ura plates. Single colonies were transferred onto a YPG plate and incubated for 2 to 3 days at 30 C. Colonies were then transferred to a new YPD plate for additional days. Finally, cell suspensions from the YPD
plate were spotted on to following plates: YPD, G418 (150 [tg/m1), 5-FOA (2 mg/ml) and SD-Ura.
Cells able to grow on YPD and 5-F0A, and unable to grow on G418 and SD-Ura plates, were picked for PCR confirmation as described, above. The expected PCR product size was 0.4-kb and confirmed the identity of the KanMX (geneticin)-sensitive, ura3-deletion strain, derived from FG-KanMX-ura3. This strain was named as FG-ura3.
Example 7 Generation of yeast with the PKL pathway
plate were spotted on to following plates: YPD, G418 (150 [tg/m1), 5-FOA (2 mg/ml) and SD-Ura.
Cells able to grow on YPD and 5-F0A, and unable to grow on G418 and SD-Ura plates, were picked for PCR confirmation as described, above. The expected PCR product size was 0.4-kb and confirmed the identity of the KanMX (geneticin)-sensitive, ura3-deletion strain, derived from FG-KanMX-ura3. This strain was named as FG-ura3.
Example 7 Generation of yeast with the PKL pathway
[082] The FG-ura3 strain was used as a parent to introduce the PKL pathway.
Cells were transformed with a 14,993-bp Kcal fragment containing the four expression cassettes from pZKAP1m-(H3C19) from Example 5. A transformant with the Kcal fragment integrated upstream of the YHR047C locus was selected and designated as strain GPY10000.
Cells were transformed with a 14,993-bp Kcal fragment containing the four expression cassettes from pZKAP1m-(H3C19) from Example 5. A transformant with the Kcal fragment integrated upstream of the YHR047C locus was selected and designated as strain GPY10000.
[083] Strains FG and GPY10000 were grown in vial cultures and their fermentation products analyzed as described in Example 1. Performance in terms of ethanol, glycerol and acetate production is shown in Table 6.
Table 6. FG versus G176 in vial assays Strain Transgene(s) expressed Glycerol Acetate Et0H
FG none 17.30 0.70 140.9 GPY10000 PKL pathway 12.94 1.86 146.3
Table 6. FG versus G176 in vial assays Strain Transgene(s) expressed Glycerol Acetate Et0H
FG none 17.30 0.70 140.9 GPY10000 PKL pathway 12.94 1.86 146.3
[084] The ethanol titer of the PKL pathway expressing GPY10000 strain was 3.8%
higher than the FG strain. Not surprisingly, the level of acetate was also elevated, which is a known property of yeast harboring the PKL pathway.
Example 8 Generation of yeast with the PKL pathway and reduced production of Dist
higher than the FG strain. Not surprisingly, the level of acetate was also elevated, which is a known property of yeast harboring the PKL pathway.
Example 8 Generation of yeast with the PKL pathway and reduced production of Dist
[085] Strain GPY10008 was generated by Cas9-mediated deletion of YIL065c (which encodes D1s1) in strain GPY10000. Specifically, a deletion was made from 4-bp before start codon to 10-bp before stop codon of YIL065c.
[086] FG yeast strain GPY10008, and its parent strain G10008, were grown in AnKom bottles and their fermentation products analyzed as described in Example 1.
Performance in terms of ethanol, glycerol and acetate production is shown in Table 7.
Table 7. GPY10000 versus GPY10008 in Ankom assays Strain Transgene(s) expressed Glycerol Acetate Et0H
GPY10000 PKL pathway 12.85 1.80 143.39 GPY10008 PKL pathway + AYJL065c 13.15 1.78 147.23
Performance in terms of ethanol, glycerol and acetate production is shown in Table 7.
Table 7. GPY10000 versus GPY10008 in Ankom assays Strain Transgene(s) expressed Glycerol Acetate Et0H
GPY10000 PKL pathway 12.85 1.80 143.39 GPY10008 PKL pathway + AYJL065c 13.15 1.78 147.23
[087] The ethanol titer of the strain with the YJL065c deletion was 2.7%
higher than the strain without the deletion. Acetate levels were approximately the same.
Example 9 Generation of a yeast combing MAL23c with the PKL pathway and reduced production of D1s1
higher than the strain without the deletion. Acetate levels were approximately the same.
Example 9 Generation of a yeast combing MAL23c with the PKL pathway and reduced production of D1s1
[088] To study the effects of MAL23c in engineered FG strain with the PKL
pathway and reduced expression of D1s1, the strain GPY10008 was used as a parent to introduce the MAL23c expression cassette, in this case at the 3' region of the YHL041w locus, otherwise as described in Example 3. GPY10008 cells were transformed with a PCR-amplified DNA
fragment containing the MAL23c expression cassette made using the pHX19 plasmid as template and primers that include flanking YHL041w locus sequences.
pathway and reduced expression of D1s1, the strain GPY10008 was used as a parent to introduce the MAL23c expression cassette, in this case at the 3' region of the YHL041w locus, otherwise as described in Example 3. GPY10008 cells were transformed with a PCR-amplified DNA
fragment containing the MAL23c expression cassette made using the pHX19 plasmid as template and primers that include flanking YHL041w locus sequences.
[089] The new FG yeast strain, designated RHY723, and its parent strain GPY10008 were grown in AnKoms bottles and their fermentation products were analyzed as described in Example 1. Performance in terms of ethanol, glycerol and acetate production is shown in Table 8, and the fermentation rate, represented by the CPI during the fermentation, is illustrated in Figure 8.
Table 8. RHY720 versus GPY10008 in Ankom assays Transgene(s) Strain Maltotriose Maltose Glucose Glycerol Acetate Et0H
expressed PKL pathway GPY10008 1.03 3.24 5.10 14.06 1.58 152.37 + YJL065cd PKL pathway RHY723 + YJL065cd 1.03 3.16 4.24 14.02 1.53 153.63 + MAL23c
Table 8. RHY720 versus GPY10008 in Ankom assays Transgene(s) Strain Maltotriose Maltose Glucose Glycerol Acetate Et0H
expressed PKL pathway GPY10008 1.03 3.24 5.10 14.06 1.58 152.37 + YJL065cd PKL pathway RHY723 + YJL065cd 1.03 3.16 4.24 14.02 1.53 153.63 + MAL23c
[090] The ethanol titer of strain RHY723 was 0.83% higher than strain GPY10008, demonstrating that MAL23c expression increases ethanol production even in yeast that also harbor the PKL pathway and do not express D1s1.
Claims (15)
1. A method for increasing the amount of alcohol produced from fermentation of a starch hydrolysate and/or increasing the rate of production of alcohol from fermentation of a starch hydrolysate, comprising fermenting the starch hydrolysate with modified yeast harboring a constitutive transcriptional activator MAL allele, where in the modified yeast produces an increased amount of ethanol at the end of fermentation or an increased amount of ethanol over a period of time compared to the amount of ethanol produced by an otherwise-identical parental yeast.
2. The method of claim 1, wherein at least a portion of the increased amount of ethanol cannot be attributed to maltose fermentation based on carbon flux through a maltose metabolic pathway.
3. The method of claim 1 or 2, wherein the level of maltose in the starch hydrolysate at the end of fermentation is about the same as the level of maltose in the starch hydrolysate at the beginning of fermentation,
4. The method of any of the preceding claims, wherein the amount of maltose in the starch hydrolysate at the beginning of fermentation is no greater than 10 g/L.
5. The method of any of the preceding claims, wherein the yeast harboring a constitutive transcriptional activator M4L allele further comprises a genetic alteration that introduces a polynucleotide encoding a polypeptide in the phosphoketolase pathway.
6. The method of any of the preceding claims, wherein the yeast harboring a constitutive transcriptional activator M4L allele further comprises an alteration in the glycerol pathway and/or the acetyl-CoA pathway.
7. The method of any of the preceding claims, wherein the yeast harboring a constitutive transcriptional activator M4L allele further comprises disruption of a gene encoding DLs1.
8. The method of any of the preceding claims, wherein the yeast harboring a constitutive transcriptional activator M4L allele comprises an exogenous gene encoding a carbohydrate processing enzyme.
9. The method of any of the preceding claims, wherein the yeast is a Saccharomyces spp.
10. Modified yeast comprising a constitutive transcriptional activator MAL
allele, and at least one additional genetic modification not associated with maltose metabolism, which yeast produces during fermentation an increased amount of ethanol at the end of fermentation compared to the amount produced by an otherwise identical parental yeast when grown in a starch hydrolysate.
allele, and at least one additional genetic modification not associated with maltose metabolism, which yeast produces during fermentation an increased amount of ethanol at the end of fermentation compared to the amount produced by an otherwise identical parental yeast when grown in a starch hydrolysate.
11. The modified yeast of claim 10, wherein the yeast further comprises a genetic alteration that introduces a polynucleotide encoding a polypeptide in the phosphoketolase pathway.
12. The modified yeast of claim 10 or 11, wherein the yeast further comprises an alteration in the glycerol pathway and/or the acetyl-CoA pathway.
13. The modified yeast of any of claims 10-12, wherein the yeast further comprises a disruption of a gene encoding DLs1.
14. The modified yeast of any of claims 10-13, wherein the yeast further comprises an exogenous gene encoding a carbohydrate processing enzyme.
15. The modified yeast of any of claims 10-14, wherein the yeast is a Saccharomyces spp.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762542761P | 2017-08-08 | 2017-08-08 | |
US62/542,761 | 2017-08-08 | ||
PCT/US2018/045789 WO2019032688A1 (en) | 2017-08-08 | 2018-08-08 | Increased ethanol production by yeast harboring constitutive transcriptional activator mal alleles |
Publications (1)
Publication Number | Publication Date |
---|---|
CA3072306A1 true CA3072306A1 (en) | 2019-02-14 |
Family
ID=63405369
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA3072306A Pending CA3072306A1 (en) | 2017-08-08 | 2018-08-08 | Increased ethanol production by yeast harboring constitutive transcriptional activator mal alleles |
Country Status (7)
Country | Link |
---|---|
EP (1) | EP3665266A1 (en) |
CN (1) | CN111201313B (en) |
AR (1) | AR112677A1 (en) |
BR (1) | BR112020002506A2 (en) |
CA (1) | CA3072306A1 (en) |
UY (1) | UY37835A (en) |
WO (1) | WO2019032688A1 (en) |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20100248233A1 (en) * | 2007-07-23 | 2010-09-30 | Dsm Ip Assets B.V. | Acetyl-coa producing enzymes in yeast |
EP2060632A1 (en) | 2007-10-29 | 2009-05-20 | Technische Universität Berlin | Method of modifying a yeast cell for the production of ethanol |
UA108853C2 (en) * | 2009-07-10 | 2015-06-25 | Galactose fermentation method | |
EP2277989A1 (en) | 2009-07-24 | 2011-01-26 | Technische Universiteit Delft | Fermentative glycerol-free ethanol production |
EP3483279A1 (en) | 2011-04-05 | 2019-05-15 | Lallemand Hungary Liquidity Management LLC | Methods for the improvement of product yield and production in a microorganism through the addition of alternate electron acceptors |
BR112016021857B1 (en) | 2014-03-28 | 2024-03-12 | Danisco Us Inc | RECOMBINANT YEAST CELL AND METHOD FOR PRODUCING ETHANOL FROM GLUCOSE |
CN104031854B (en) * | 2014-06-20 | 2017-02-22 | 广西科学院 | Saccharomyces cerevisiae gene engineering strain for improving ethanol tolerance and construction method of saccharomyces cerevisiae gene engineering strain |
-
2018
- 2018-08-07 UY UY0001037835A patent/UY37835A/en not_active Application Discontinuation
- 2018-08-08 BR BR112020002506-2A patent/BR112020002506A2/en not_active Application Discontinuation
- 2018-08-08 WO PCT/US2018/045789 patent/WO2019032688A1/en unknown
- 2018-08-08 EP EP18760106.7A patent/EP3665266A1/en not_active Withdrawn
- 2018-08-08 AR ARP180102262 patent/AR112677A1/en not_active Application Discontinuation
- 2018-08-08 CA CA3072306A patent/CA3072306A1/en active Pending
- 2018-08-08 CN CN201880065244.4A patent/CN111201313B/en active Active
Also Published As
Publication number | Publication date |
---|---|
WO2019032688A1 (en) | 2019-02-14 |
UY37835A (en) | 2019-03-29 |
CN111201313B (en) | 2024-06-14 |
AR112677A1 (en) | 2019-11-27 |
BR112020002506A2 (en) | 2020-08-11 |
CN111201313A (en) | 2020-05-26 |
EP3665266A1 (en) | 2020-06-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20190276905A1 (en) | Yeast with improved alcohol production | |
EP3634982A1 (en) | Yeast with improved alcohol production | |
US20230002793A1 (en) | Reduction in acetate production by yeast over-expressing mig3 | |
US11447783B2 (en) | Reduction in acetate production by yeast over-expressing PAB1 | |
EP3555295A1 (en) | Bifunctional phosphoketolase-phosphotransacetylase fusion polypeptides | |
US20210292734A1 (en) | Increased alcohol production from yeast producing an increased amount of active crz1 protein | |
US20210395756A1 (en) | Over expression of ribonucleotide reductase inhibitor in yeast for increased ethanol production | |
WO2019173217A1 (en) | Compositions and methods for increasing ethanol production by yeast using gcy1 and dak1 | |
US20210179674A1 (en) | Yeast with improved alcohol production | |
US12139704B2 (en) | Yeast with improved alcohol production under high dissolved solids conditions | |
US12209236B2 (en) | Overexpression of fumarate reductase results in an increased fermentation rate in yeast | |
US20230116556A1 (en) | Increased ethanol production by overexpression of jid1 in yeast | |
US20220073954A1 (en) | Hybrid yeast with increased ethanol production | |
US20210332091A1 (en) | Over-expression of gds1 in yeast for increased ethanol and decreased acetate production | |
CN111201313B (en) | Increasing ethanol production by yeast with constitutive transcriptional activator MAL alleles | |
US20210032642A1 (en) | Increased alcohol production from yeast producing an increased amount of active hac1 protein | |
EP4423262A1 (en) | Reduction in acetate produced by yeast with reduced expression of rsf2 or tda9 | |
EP4355881A1 (en) | Increased ethanol production by over-expression of kgd2 in yeast | |
US20250043236A1 (en) | Over-expression of cytochrome b2 in yeast for increased ethanol production | |
WO2021022097A1 (en) | Over-expression of adh5p for increased ethanol production by yeast | |
EP3938519A1 (en) | Over-expression of fumarate-succinate transporter in yeast for increased ethanol and reduced acetate production | |
WO2018136385A1 (en) | Modified yeast cells that overexpress a dna polymerase subunit | |
CA3073387A1 (en) | Modified yeast comprising glucose-specific, atp-mediated transporters |